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Abstract
Memory T Cells and the Endothelium in Allograft Rejection
Stephen Lawrence Shiao 
2007
Organ transplantation has become increasingly important as a treatment for many 
human diseases. Despite the dramatic improvements in immunosuppression in recent 
years, acute and chronic rejection remain significant problems. It has become 
increasingly evident that the presence of T cell memory correlates with both acute and 
chronic rejection episodes. Endothelial cells (EC) have been shown to preferentially 
activate memory T cells and, as the lining of every transplanted organ, they are in a 
unique position to provide signals to alloreactive memory T cells. EC activation of 
memory T cells depends in part on the costimulatory molecule LFA-3 in addition to other 
signals. The nature of these other signals is not well understood. In this dissertation I 
further explore the mechanisms by which EC activate memory T cells and investigate the 
role that these mechanisms play in a model of memory T cell mediated allograft 
rejection.
Several newly described costimulatory pathways, ICOS-ICOSL, 4-1BB-41BBL, 
and OX40-OX40L, have recently been recognized as important players in the generation 
and function of memory T cells. EC can express all three of the ligands from these 
pathways and also increase expression in response to the cytokine tumor necrosis factor 
(TNF) and in co-cultures with T cells. Furthermore, blockade o f these pathways using
i
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monoclonal antibodies in co-cultures causes reductions in T cell production of IFN-y and 
IL-2 as well as decreased T cell proliferation.
To examine the contribution of memory T cells to allograft rejection in vivo, I 
describe a chimeric model of human skin grafted onto SCID mice that are adoptively 
transferred with various subsets of human T cells. In this model, rejection of the human 
skin by the transferred T cells is mediated by memory T cells alone. Using this model, 
the effect of different costimulatory pathways on allograft rejection is tested. 
Interestingly, blockade o f any of the three costimulatory pathways can diminish the T cell 
response to the allograft. The role of the B7-CD28 pathway is also examined and found 
to partially contribute to the memory T cell response.
Finally, using observations that memory T cells can be further divided into two 
functionally distinct subsets known as central and effector memory T cells, the response 
of these two subsets to EC is explored. Central memory T cells respond to EC by 
producing IL-2 while effector memory T cells generate IFN-y. The basis for this 
difference may be due to the differential expression and sensitivity o f the two subsets to 
costimulation by CD27 and CD28. Further, in the chimeric human-SCID model effector 
memory T cells alone can mediate allograft rejection while central memory T cells 
cannot.
Our results strongly support the idea that the EC capacity to activate memory T 
cells and its subsets depends in part on the CD28-B7 pathway and memory T cell specific 
costimulatory molecules. Furthermore, targeting CD28 or these molecules in vivo can 
attenuate allograft rejection mediated by memory T cells.
ii
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CHAPTER I - INTRODUCTION
More than 25,000 organ transplants are performed annually with over 93,000 
patients waiting to receive a transplant in the United States alone (1) and what was once 
an experimental exercise has now become the treatment o f choice for many diseases. 
The technical aspects of organ transplantation were resolved by 1964 when Alexis Carrel 
won the Nobel prize in 1964 for the description of anastomotic technique and 
experimental organ transplantation (2). However, the understanding of the biological 
barriers to transplantation lagged far behind the surgical technique.
Peter Medawar was the first to propose the idea that the immune system could 
reject a transplanted organ (3, 4). The basis for this idea came from Medawar’s work 
using skin grafts on bums. He discovered that skin grafted from a given donor lasted 
about 10 days, but a second graft was rejected immediately. Medawar suggested that the 
initial and accelerated rejection were an immunological process whereby the immune 
system “remembered” what the graft looked like and promptly rejected it. Medawar’s 
experiments coincided with Frances Macfarlane Burnet’s work on a second critical 
observation. Bumet found that chick embryos and fetal animals did not produce 
antibodies and that immunocompetence developed slowly over time (5). This finding led 
to the concept that during embryonic development there is a period of “self-recognition” 
where tolerance to a given antigen is developed by fetal exposure to “non-self antigens.” 
In other words, the immune system had to be clonally selected and taught about self and 
non-self (2). Combining Burnet’s observation about self versus non-self and his own 
work with skin grafts, Medawar with his postdoctoral fellows Rupert Billingham and 
Leslie Brent demonstrated that neonatally acquired transplant tolerance could be achieved
1
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in mice by inoculating embryos or newborn mice with allogeneic cells (6). These critical 
experiments led to the initial understanding that the immune system was responsible for 
rejection due to its ability to identify which cells were self and which were not. The 
molecular basis of self recognition came only a few years later with the description of the 
first leukocyte antigen called MAC in 1958 by Jean Dausset, which became known as the 
major histocompatability complex (MHC) (7). These critical experiments formed the 
foundation for the biological understanding of transplant rejection, however, it would 
take several decades before the discovery of a fungal metabolite known as cyclosporin 
made transplantation a clinical reality (8, 9).
Despite the introduction of new protocols and immunosuppressive reagents over 
the past twenty years, incidences of rejection at 1 year remain at 20% for kidneys, 30% 
for livers and nearly 40% for hearts (10). Furthermore, current immunosuppressants also 
fail to control long-term immune responses to the organ which can lead to more chronic 
forms of rejection such as coronary allograft vasculopathy in heart transplants and 
chronic allograft nephropathy in renal transplants. The current drugs also have toxic side 
effects that can damage the transplanted organ (such calcineurin inhibitory mediated 
nephrotoxicity) as well as contribute to the incidence of malignancy, infection, diabetes, 
hypercholesterolemia and cardiovascular disease (11). Therefore, finding better and 
more specific means o f immunosuppression continues to be a major goal of 
transplantation.
In the search for better immunosuppression, it is important to understand why 
current immunosuppressive regimens fail. One hypothesis is that there are portions o f the 
immune system that are resistant to immunosuppression and there is increasing
2
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recognition that one reason for the failure of immunosuppression in both the acute and 
chronic settings may be the presence of immunological memory. In the setting of 
transplantation it has long been recognized that the presence of preformed alloreactive 
antibodies may result in hyperacute allograft rejection (12). Experimental models as 
early as the 1970s also recognized the potential for alloreactive memory T cells to elicit 
allograft rejection (13, 14). Since then, the role of T cell immunologic memory was 
largely forgotten because of the initial successes with immunosuppression. However, 
with advances in our understanding of the immune system it has now become evident that 
memory T cells play a critical role in the immune response to allograft and understanding 
their biology has become a major focus of transplantation research.
1.1 T CELL MEMORY
One of the defining features of the immune system is the concept of immunologic 
memory. Immunological memory can be defined as the faster and stronger response of 
the immune system in a secondary response to an Ag compared to a primary response to 
the same Ag (15, 16). Immunologic memory is also thought to last for the lifetime o f an 
organism. The faster and stronger secondary response of the immune system results from 
quantitative as well as qualitative changes in the cell populations that respond to a given 
Ag. Among these changes are increases in the frequency of responding cells, changes in 
the activation requirements and alterations of their migratory patterns. For example, in 
humoral responses, there is a greater frequency o f  antigen reactive cells specific for an 
antigen, as well as antibody products that are clearly different from the initial response 
(17). For T cells, there is a similar increase in frequency of antigen reactive cells and a
3
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more rapid acquisition of effector function in a recall response. In order to more closely 
examine the properties o f memory T cells it is important to understand the primary 
response as a comparison.
The primary response
Naive T cells may be defined as T cells that have not encountered antigen and the 
primary response describes their response to the first exposure. Before contacting 
antigen, naive T cells circulate between secondary lymphoid organs such as the spleen 
and lymph nodes by traveling in the blood or lymph (18, 19). The continuous migration 
of naive T cells through the secondary lymphoid tissues is important for T cells to 
efficiently encounter antigens. To encounter antigens, naive T cells must make contact 
with specialized antigen presenting cells (APCs) such as dendritic cells (DC) that present 
antigens in the form of peptide fragments bound to major histocompatibility complex 
(MHC) molecules (20). In animals that have not encountered antigen, the MHC complex 
is bound to self peptides which are largely ignored by the naive T cells. Naive T cells 
live for extended periods of time in a metabolically quiescent state, and experiments in 
mice have demonstrated that their survival in this state depends on continually receiving 
low-levels signals from self-peptide/MHC (21-24) and IL-7 (25, 26).
Without the presence of foreign antigen, naive T cells circulate through the 
secondary lymphoid organs contacting self-peptide/MHC indefinitely. However, once 
naive T cells recognize an APC bearing a foreign peptidc/MHC complex, the naive T 
cells undergo a series of changes in migration and function in response to the foreign 
antigen. T cells recognize antigens through highly-specific interactions between their T
4
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cell receptor and peptide/MHC complexes. Upon recognition of a foreign peptide, na'ive 
T cells stop circulating and increase contact between the T cell and the APC in part 
through the formation of structures known as synapses (27-30).
A synapse refers to the grouping of molecules formed at the contact site between 
the T cell and the APC and reflects the organization of the signaling molecules used in T 
cell activation (31, 32). The synapse is composed of a cluster of TCR molecules and 
accumulation of signaling molecules such as LCK, LAT, and PKC0 and 
costimulatory/adhesion molecules including CD28, CD2 and LFA-1. The costimulatory 
and adhesion molecules are thought to provide key second signals as well as enhance 
TCR triggering by stabilizing the synapse or recruiting other intracellular signaling 
molecules (33). Once the T cell has been triggered, the T cells undergo substantial 
proliferation and differentiation into effector cells that generally lead to the elimination of 
the source o f the foreign antigen. Once the source o f the antigen is eliminated, the 
effector cells are rapidly eliminated and memory T cells are formed (34).
When the organism re-encounters an antigen, the response of memory T cells 
differs from that of naive T cells in several significant ways. The first major difference is 
in the size and speed of the response. The secondary response is generally both larger 
and more rapid than the primary response. The second major difference is the conversion 
to effector cells. Na'ive T cells when they are activated produce IL-2 initially and require 
several rounds of proliferation before they start to express effector molecules. In 
response to antigen, memory T cells become effector T cells much more quickly. 
Identifying the mechanisms that are responsible for these differences in the secondary 
response is the basis for studies of T cell memory.
5
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Surface Markers o f  Naive, Effector and Memory T  cells
Many of the differences in activation potential and homing between memory and 
na'ive T cells are reflected in the surface molecules used to distinguish them. These 
molecules include those involved in trafficking and adhesion (CD44, C D lla , CD62L); 
TCR signaling (CD45) and cytokine and chemokine responses (CD25 (IL-2Ra), CD122 
(IL-2/15R|3), CCR7) (see Table 1-1).
In humans, naive T cells are CD45RA positive and CD45RO negative whereas 
memory T cells are the converse, CD45RO positive and CD45RA negative (35, 36). The 
antibody used to identify CD45RO (UCHL1) identifies an epitope that is present in the 
absence of all the other CD45R isoforms (A, B, and C). In the mouse, there is no 
equivalent of CD45RO that has been studied and so some investigators use CD45RB, 
however CD45RB has been shown to change with activation or cytokine treatment (37, 
38). Therefore, in the mouse, unlike in humans, memory T cells are most commonly 
defined using the adhesion molecule CD44 with na'ive T cells being CD44 low and 
memory T cells being CD44 high. The only concern is that this pattern is only true for 
the C57BL/6 strain and is less clear for other strains (39). The rat does not upregulate 
CD44 on its memory T cells and therefore loss of CD45RC (OX-22) has been used (37). 
In other large mammals such as sheep, adhesion molecules such as CD62L and CD 11 a 
have also been used to identify memory T cells (40).
6
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Memory
Naive Effector Effector Central
CD11a Lo Hi Hi Hi
CD25 Lo Hi Lo Lo
CD44 Lo Hi Hi Hi
CD62L Hi Lo Lo Hi
CD69 Lo Hi Lo Lo
IL-2/15R Lo Hi Hi Hi
CCR7 Hi Hi Lo Lo
CD45RA Hi Lo Lo Lo
CD45RO Lo Hi Hi Hi
CD45RB Hi Lo Lo Lo
Table 1-1 Surface markers o f  human naive, effector and memory T cells.
Relative expression of several commonly used markers for distinguishing na'ive from 
effector and both central and effector subsets of memory T cells.
7
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As evidenced by the diversity of different markers used to identify memory cells, 
there are a number o f complications to isolating a true memory T cell population. One 
problem with identifying memory T cell populations is that effector cells often share 
some of the same surface molecules as memory T cells most particularly elevated CD44. 
However, it is possible to use other markers of activation such as CD25 and CD69 to 
distinguish effector cells from bona fide memory T cells (41, 42). Another problem is 
that the memory phenotype can be recapitulated in certain situations without having seen 
foreign antigen including lymphopenia-induced proliferation and extrathymic 
development. In both of these situations, na'ive T cells acquire the phenotype o f memory 
T cells and in some cases even memory T cell functions like rapid IFN-y production (43- 
45). However, all these studies have been carried out in mice and it is unclear what role 
these two factors play in determining the memory T cell pool in humans.
In addition to distinguishing between a naive and memory T cell pool, it has 
become increasingly clear that memory T cells are heterogeneous and can be further 
divided into different subsets based on the expression of the adhesion molecule CD62L 
(L-selectin) and the chemokine receptor CCR7 (46). These two markers define two 
subsets that are distinct in their homing potential and functional capacity. Central 
memory T cells ( T c m ) ,  CD62L+CCR7+, are thought to circulate through the secondary 
lymphoid organs like naive T cells and have higher proliferative potential but lower 
immediate effector function. In contrast, effector memory T cells ( T e m ) ,  CD62L-CCR7-, 
circulate to the periphery and can rapidly secrete cytokines and other effector molecules.
Thus, despite some confusion about which markers to employ in distinguishing 
the different subsets especially between species, it is possible to differentiate between
8
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naive, effector and memory T cells as well as different subsets within memory T cells 
using surface markers. Studies carried out on these distinct populations have indicated 
that as suggested by their different surface phenotypes, that the three groups possess 
significantly different functional capacities.
Functions o f  Naive v.s\ Memory T cells
Following clearance of a given antigen in a primary response, there is a massive 
culling of effector cells. Despite this massive extinction of responding T cells, the 
precursor frequency of Ag-specific memory T cells is significantly greater compared to 
naive T cells (47, 48). This increased frequency in part explains the increased speed and 
size o f secondary responses. This can be seen in studies done in mice, where treatments 
that decrease the numbers of Ag specific memory CD8+ T cells showed diminished 
secondary responses to those Ag (49, 50).
In addition to greater numbers, memory T cells also possess different homing 
potentials. As discussed above, memory T cells can be subdivided into two separate 
subsets based on expression of CD62L and CCR7 (46). Tcm have a circulation pattern 
that closely resembles naive T cells in terms o f their distribution in the lymphoid tissues. 
Expression of CD62L and CCR7 allows both Tcm and naive T cells to enter lymph nodes 
via high endothelial venules (HEV). Like naive T cells, Tcm appear to require 
stimulation in secondary lymphoid organs in order to acquire effector function (46, 51, 
52). By contrast, Tem, like effector cells, are CD62L and CCR7 low and consequently 
migrate through non-lymphoid tissues. They also display constitutive CTL function and 
cytokine synthesis in vivo (34, 51, 53, 54). The positioning of TEM allows them to
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provide immediate immunity in a secondary response. This homing potential may in part 
account for the faster secondary responses compared to naive T cells.
In addition to quantitative differences in precursor frequency and homing, 
memory T cells are also qualitatively different from naive T cells. In general, memory T 
cells have a lower activation threshold than naive T cells. They possess the ability to 
respond to low affinity/avidity interactions thus allowing them to respond to a much 
lower amount of antigen compared to naive T cells (23, 55-57). Part of this lower 
threshold is related to the fact that memory T cells also have a reduced reliance on APC 
provided costimulation (58, 59). In fact, memory T cells have been shown to be less 
dependent on the B7/CD28 pathway and independent of the CD40/CD154 pathway (60). 
Memory T cells can also become activated in the absence of secondary lymphoid organs 
(61). Furthermore, T c m , despite their similar migratory potential, are clearly less 
quiescent than their naive counterparts. For instance, CD8+ Tcm express high levels of 
mRNA suggesting that they are in the G1 phase o f cell cycle (62) and show a much 
shorter lag time for entering the cell cycle (56, 63-65). Additionally, both Tcm and Tem 
also have much faster kinetics for synthesizing cytokines, differentiating into CTL and 
migrating to non-lymphoid tissues (56, 62, 63, 65-68).
In sum, memory T cells can detect lower concentrations o f their cognate antigen, 
expand far more rapidly, produce a greater amount and broader array of cytokine on a 
per-cell basis, and survive longer than either naive or effector cells. It is these unique 
properties o f  memory T cells that not only serve as the basis for both the beneficial 
effects as in the case of vaccines but also the harmful effects as in autoimmunity and 
transplant rejection.
10
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1.2 T CELL COSTIMULATION
In order for T cells to see antigen, there is significant evidence supporting the 
concept o f the two-signal hypothesis o f T cells activation (69, 70). The two-signal 
hypothesis results from observations that peptide/MHC complexes alone are in general 
insufficient to activate T cells (71). Therefore, in order for T cells to be activated, 
another signal is required to amplify the weak signal coming from the T cell receptor 
(TCR). This second signal, known as the co-stimulatory signal, is a critical feature of 
competent APCs that provide this signal in addition to the antigen specific signal (signal 
one) to initiate an immune response. Many stromal and epithelial cells lack the 
expression o f these co-stimulatory molecules and thus even in the situation where they 
express functional peptide/MHC complexes they are unable to activate T cells. 
Costimulatory molecules can be divided along structural lines into two families, the Ig 
superfamily and the tumor necrosis factor (TNF) family. Included in the Ig superfamily 
are the well-known CD28/CTLA-4/B7 family and CD2/LFA-3. The TNF family 
includes CD40/CD40L (CD 154), CD27/CD70, CD 134 (OX40)/OX40L, and CD 137 (4- 
lBB)/4-lBBL (See Table II-1).
The Ig superfamily o f  costimulatory molecules
One of the first costimulatory pathways to be identified in mice and thus perhaps 
the best characterized is the CD28/B7 family (72-77). The B7-l/B7-2:CD28/CTLA-4 
pathway consists of two B7 family members B7-1 (CD80) and B7-2 (CD86) that both 
bind the same two receptors, CD28 and CTLA-4 (78). Both receptors have distinct 
kinetics and binding affinities for B7-1 and B7-2 (79). CD28 is constitutively expressed
1 1
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on the surface of T cells while CTLA-4 is upregulated with activation. CTLA-4 also has 
a much higher affinity for both B7-1 and B7-2. This difference in kinetics and affinity is 
also reflected in the function of these two receptors in T cell activation. Engagement of 
CD28 in conjunction with TCR engagement allows T cells to make IL-2 and survive. 
The higher affinity CTLA-4 gets expressed later and both competes with CD28 and 
delivers a negative signal to down regulate the T cell response. Professional APCs like 
dendritic cells and B cells express low levels of B7-2 constitutively, but rapidly 
upregulate both B7-2 and B7-1 on their surface when they become activated (i.e. through 
TLR signals or cytokines). The interaction between B7s and CD28 are critical for the 
activation of naive T cells (80).
There have also been several recently described new members of the B7 family 
including ICOS-ICOSL and PD-1/PD-L1/2 (81). ICOS is upregulated on both CD4+ and 
CD8+ T cells following activation and is present on both effector and memory T cells 
(82-84). ICOSL is expressed on the surface of B cells, macrophages, dendritic cells, and 
endothelial cells (85, 86). ICOS-ICOSL has been shown to play an important role in T 
cell activation, differentiation, and effector responses. The key differences between the 
ICOS-ICOSL pathway and the CD28-B7 pathway are that ICOS signaling can only be 
delivered after T cells have been activated and that signaling does not upregulate IL-2 
production (87). Therefore, it seems that ICOS plays a role in propagating effector 
function, but does not have a role in the primary response.
PD-1 is induced on peripheral CD4+ and CD8+ T cells, B cells and monocytes 
upon activation (88). The ligands for PD-1, PD-L1 and PD-L2, are widely expressed in 
both lymphoid and non-lymphoid tissues including B, T, myeloid and DC, but also EC
12
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and other epithelial cells (89, 90). The PD-1/PD-L1/PD-L2 pathway has a critical role in 
regulating T cell activation and tolerance. PD-1 appears to regulate inflammatory 
responses in peripheral tissues and help maintain tolerance particularly in CD8+ T cell 
responses (91, 92). In transplantation, PD-1 stimulation by PD-Lllg in combination with 
other blockade significantly inhibited naive T cell responses in cardiac and islet allografts 
(93, 94).
The CD2/LFA-3 (CD58) interaction was the first costimulatory pathway to be 
identified in T cell activation and remains an important costimulatory pathway (95-97). 
Originally known as LFA-2, CD2 is expressed on the majority of T cells while LFA-3 
can be found on dendritic cells, macrophages, B cells, fibroblasts and ECs (98-101). The 
CD2-LFA-3 interaction has been shown to be an important pathway independent of 
CD28 to activate T cells and part of its costimulatory function may be mediated by its 
adhesive properties (102, 103). No rodent homologue o f LFA-3 has been identified, 
however the related molecule CD48 (blast-1, BCM1, 0X 45) has been characterized as a 
CD2 ligand in both mice (104) and rats (105). Humans also express CD48, but it has 
such a low affinity binding to CD2 that it is not clear that the CD2-CD48 interaction is 
physiologically relevant in humans (106). CD2-CD48 interactions in mice, like their 
human counterpart, appear to be important in T cell activation as demonstrated in a 
mouse allograft model (107, 108), but as the ligand is not equivalent it is not clear that 
murine results can be accurately compared to humans. However, studies have been done 
using a chimeric human SCID mouse model and these demonstrated that inhibition of the 
CD2/LFA-3 pathway with blocking antibodies against LFA-3 or an LFA-3Ig fusion 
protein can significantly diminish allograft rejection (109).
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The TNFR fam ily o f  costimulatory molecules
The TNFR family members can be divided into three groups, death domain (DD)- 
containing receptors, decoy receptors and TNF receptor associated factor (TRAF) 
binding receptors (110, 111). TNFR1 and Fas are examples of DD-containing receptors. 
They activate caspase cascades leading to apoptosis. TRAF binding receptors do not 
contain DDs, but possess motifs of 4-6 amino acids that recruit TRAF proteins (112). All 
costimulatory members o f the TNFR family are TRAF binding receptors and in particular 
they all bind TRAF2 in conjunction with various other TRAF proteins (112) leading to 
NF-kB (113-115) translocation downstream of all the receptors. CD27 and 4 -IBB have 
also been shown to lead to p38 MAPK (116) and JNK activation (117, 118). The result 
of this signaling is to enhance survival signaling, cytokine production and cellular 
proliferation of T cells.
The most well-known TNFR receptor pair in T cell responses is CD40/CD40L 
(CD154). CD40 is expressed on B cells (119), DC, monocytes, macrophages, EC (120) 
and VSMC (121) and is inducible by cytokines such as TNF and interferons (122-124). 
Its ligand CD 154 is expressed on activated CD4+ and CD8+ T cells, NK cells, 
monocytes, B cells, activated DC, EC and VSMC (119, 121, 124). CD40-CD154
interactions play a critical role in humoral immunity, activation of APC costimulatory 
function as well as activation of macrophages and the endothelium (124, 125). The broad 
reciprocal expression of the receptor and ligand pairs suggests that this pair may be used 
for bi-directional signaling, for example APC activate T cells through CD40L (126) 
while the T cells simultaneously modify the activity o f the APC through CD40 (127).
14
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Thus, the CD40-CD40L pathway may play a more complex role in the immune response 
beyond its pure costimulatory function.
CD27 is expressed on NK cells, B cells, naive and Tcm CD4+ and CD8 + T cells. 
CD27 expression increases transiently with activation and gradually decreases with 
successive rounds o f division (128, 129). Its loss is thought to correlate with acquisition 
of effector function (130, 131). In addition to correlating with effector function, 
engagement of CD27/CD70 costimulatory pathway has been shown to enhance CD8 + 
effector/memory T cell functions (132, 133). Its ligand, CD70, is found on activated T 
cells, B cells and DC, but not resting EC (134, 135). In mice, CD70 can be induced on B 
cells and DC by anti-CD40 or LPS and on DC with GM-CSF (136) and it is unknown 
whether it is similarly inducible in humans.
0X 40 (CD134), originally identified in the rat (137), has its expression restricted 
to activated T cells in both mice and humans (138). In a number of conditions 0X 40 is 
preferentially expressed on activated CD4+ T cells rather than CD8 + T cells suggesting 
that there may be a larger role for 0X 40 in CD4 mediated processes (139). Engagement 
o f CD28 enhances the kinetics of 0X 40 expression and expression of 0X40 can be 
prolonged in a number of inflammatory conditions (140-143). 0X 40 does not have the 
ability to replace CD28 or affect the initial rate of cell division in naive T cells, but does 
allow for recovery of greater numbers o f T cells later in the response likely due to effects 
of 0X40 signaling on induction of key survival molecules like Bcl-2 and Bcl-XL (140, 
144, 145). In part through the induction o f  these survival m olecules 0 X 4 0  signaling 
plays a critical role in the generation and function of memory T cells, particularly CD4+ 
memory T cells (146, 147). OX40L is expressed on activated B cells (148) and DC (149,
15
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150), plasmacytoid DC (151), and EC (152, 153). It can be induced by CD40L-activation 
on DC (154).
4 -IBB was originally characterized as a molecule expressed on activated T cells 
(155), though it has since been found on a number o f other cell types including DC (156), 
Mo (157), follicular DC (158), and NK cells (159). Current evidence indicates that both 
CD4+ and CD8 + T cells can express 4 -IBB, but in several circumstances CD8 + T cells 
can upregulate 4-1BB more rapidly and to higher levels than CD4+ T cells (139, 160). 4- 
1BB provides signals in a CD28 independent manner that lead to enhanced cell division 
and improved survival (161, 162). Studies in mice and humans have shown that 4 -IBB 
engagement prevents activation-induced cell death in T cells and agonistic antibodies to
4 -IBB both in vitro and in vivo show prolonged T cell survival post-activation with 
greater effects on CD8 + T cells (163-167). Signaling through the 4 -IBB pathway is also 
critical for the survival and function o f memory CD8 + T cells (147). The ligand for 4- 
1BB, 4-1BBL, is expressed on activated macrophages, DC and B cells (168, 169). 4- 
1BBL expression can be upregulated on both B cells and DC via CD40 stimulation (170, 
171). There are also reports that 4-1BBL engagement on human monocytes with 4 -IBB 
fusion proteins induces reverse signaling implying that like CD40L there may be multiple 
bi-directional effects of receptor-ligand engagement (172, 173).
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Costimlatory Expression of Costimulatory Ligand
Structural Family Molecule Molecule Ligand Expression
Ig Superfamily CD28 T4 , 8, N, E, M B7-1 (CD80), B7-2 (CD8 6 ) B, Mo, DC, Te
CTLA-4 T4, 8, E, M B7-1 (CD80), B7-2 (CD8 6 ) B, Mo, DC, Te
ICOS T4, 8, E, M» NK ICOSL B, Mo, DC, T, EC
PD-1 T4i8, B, Mo PD-L1, PD-L2 B, Mo, DC, T, EC
CD2 T ’ LFA-3 (CD58) B, Mo, DC, T, EC
TNF Superfamily CD154 (CD40L) T4 ,8 , NK, Mo, B, Eo, EC, V, DC CD40 B, DC, Mo, EC, V
0X40 (CD 134) T4, 8, E, M OX40L B, DC, T, EC
4-1BB (CD137) T4.8, e , M i B, Mo, NK, DC, Eo 4-1BBL B, Mo, DC
CD27 T4 , 8, N, C M . NK. B CD70 B, DC, Te
GITR T, Treg GITRL B, Mo, DC, EC
Table II - l . Costimulatory molecules and their expression.
The costimulatory molecules discussed in the introduction are listed here along with their 
known expression patterns. T = T cell, 4 = CD4+ T cells, 8  = CD8 + T cells, N = Na'ive T 
cells, E = Effector T cells, M = Memory T cells, CM = Central Memory T cells, Treg = 
Regulatory T cell, NK = Natural killer cell, B = B cell, Mo = monocyte/macrophage, Eo 
= Eosinophil, DC = Dendritic cell, V = Vascular Smooth Muscle Cell
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1.3 ENDOTHELIAL CELLS (EC) AS ANTIGEN PRESENTING CELLS
Endothelial cells (EC), the cells that line the entire vascular tree, are specialized
cells that have an important role in regulating the communication o f oxygen, nutrients, 
different proteins and cells between the different organs o f the body. With regards to the 
immune system, they play a pivotal role in the recruitment of immune cells to sites of 
inflammation. As such, they are uniquely positioned to serve as sentinels o f the 
peripheral tissue conveying to immune cells the status o f the organs beyond them. It is 
this proximity to immune cells such as T cells and the need to for tissues to communicate 
to T cells within blood vessels that led to the hypothesis that EC serve as intermediaries 
in this process and that an important part o f this role is the ability of EC to activate T 
cells.
EC can express MHC molecules in vivo and in vitro
Antigen presenting cells (APC) are specialized cells that express surface 
molecules that synergize with specific antigens and present them to T cells. Among these 
specialized molecules are the major histocompatability complex (MHC) molecules whose 
only known function is to present peptides to T cells. Professional antigen presenting 
cells include dendritic cells, macrophages and B cells and have the capacity to activate 
naive T cells.
In humans and other large mammals (not including mice or other rodents), all 
endothelial cells strongly express MHC class I. MHC Class II molecules are also 
constitutively expressed, but only on some ECs including postcapillary venules, veins, 
some arteries and most of the microvasculature (174-177). Expression of the MHC 
molecules in vivo may depend on basal levels of circulating IFN-y. This idea is
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supported by the fact that artery segments or skin transplanted into immunodeficient mice 
show decreased MHC class I and loss of expression o f MHC class II both of which can 
be restored by the addition of exogenous IFN-y (178, 179). In vitro, a similar 
phenomenon is observed, whereby under standard culture conditions, human EC express 
MHC class I, but not MHC class II. MHC class I can be augmented by tumor necrosis 
factor (TNF) and Type I interferons, while IFN-y can induce class II (180-184). 
Consistent with the expression of MHC, EC can also express key proteins involved in the 
assembly of the MHC and peptide processing such as invariant chain and TAP 1/2 (181, 
185). Experiments using cultured human EC to activate peptide-specific T cell clones 
further demonstrates that EC can process and present functional peptide-MHC complexes
(186), though recent data has suggested that EC may present a distinct, less immunogenic 
repertoire in their peptide-MHC complexes compared with other types of APCs or 
epithelial cells (187).
EC express costimulatory molecules
EC can also provide costimulation via cell-surface signaling molecules, adhesion 
molecule and cytokines in addition to the TCR signal they provide via peptide-MHC 
complexes. EC have been shown to express several members of both the Ig superfamily 
and TNFR family on their cell surface.
In general, human EC do not express B7 molecules (188, 189) which in part 
explains their inability to activate naive T cells. However, there is evidence that EC may 
induce B7 expression on T cells and provide B7 signaling via a trans costimulatory 
mechanism (190). There is also some suggestion that EC from different locations such as
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cardiac microvascular EC and brain EC may be capable of expressing B7 molecules (191,
192). ICOSL is constitutively expressed on the surface of HUVEC and has been shown 
to be induced by TNF and IL-1 on HUVEC in an NF-kB dependent manner (8 6 , 193). 
HUVEC expressing ICOSL in vitro can activate memory CD4+ and CD8 + T cells (8 6 ,
193). In addition to the costimulatory molecules B7 and ICOSL, EC have also been 
demonstrated to express the inhibitory B7 molecule PD-L1 (89, 194) and to upregulate 
expression of PD-L1 with treatment from any of the interferons (89, 195). EC expression 
o f PD-L1 has a role in inhibiting CD4+ T cell cytokine synthesis and CD8 + T cell 
cytolytic function (89, 90, 194). EC also constitutively express LFA-3 (100). There is 
much evidence that CD2-LFA-3 interactions between EC and T cells is a critical 
component of the costimulatory signals delivered by EC to T cells (188, 196, 197).
EC also have been described to express two of the TNFR family members 
including CD40-CD154 (124) and OX40L (152). EC have been shown to express CD40 
constitutively both in vitro and in vivo and upregulate its expression when treated with 
TNF, IL-1, IFN-y and IFN-P (120, 122). There have also been reports of EC expressing 
CD154 which is upregulated with IL-1, TNF and IFN-y (121). CD70 is not expressed on 
resting endothelium and it is not known if  it is inducible on EC (135). EC also express 
OX40L constitutively, but there is not much known about its regulation (152). 
Expression of 4-1BBL on EC has not been reported, though 4-1BBL expression has been 
reported on cardiac myocytes and aortic tissue (198, 199).
In sum, many EC have been previously reported to express the known 
costimulatory molecules ICOSL, PD-L1, CD40/CD154 and OX40L. Therefore, while 
most EC do not express the B7 molecules and thus cannot fully activate na'ive T cells,
20
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they possess sufficient alternative costimulatory molecules which may play a large role in 
the activation o f memory T cells. The CD2/LFA-3 and ICOS/ICOSL interactions in 
particular have been demonstrated to be important in EC capacity to activate memory T 
cells and will be discussed later. EC also express adhesion molecules such as ICAM-1, 
ICAM-2 and hyaluronan (200) and cytokines such as IL-1 a  (201), IL-15 (202), IL - 6  
(203), IL-11 (204) and IL-18 (205) that may provide additional costimulation to T cells.
EC can costimulate T cells in vitro
Compared to other stromal or epithelial cell types, cultured human EC have a 
unique capacity in that they can activate proliferation of allogeneic T cells freshly 
isolated from peripheral blood (206, 207). The kinetics of this activation is comparable 
to that observed with professional APC such as allogeneic blood mononuclear cells, but 
the magnitude o f the response in co-cultures between allogeneic T cells and endothelial 
cells is generally smaller (180). EC have been shown to activate both CD4+ and CD8 + T 
cells in vitro (196, 208, 209). Both CD8 + and CD4+ T cells secrete IFN-y in response to 
co-culture with EC. Isolated CD8 + T cells co-cultured with allogeneic EC make some 
IL-2 and proliferate, but purified CD4+ T cells make much more IL-2 and proliferate to a 
much greater extent (209, 210). However, the CD4+ response depends upon 
pretreatment of the ECs with IFN-y (or preincubation with natural killer or CD8 + T cells) 
to cause class II MHC molecule expression, whereas constitutive levels of MHC class I 
expression are sufficient to activate CD8 + T cells (209).
Studies using limiting dilution assays to quantify the number of T cells that 
respond to allogeneic EC have indicated that the frequency of responding T cells is
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significantly lower than the frequency of T cells responding to professional APC like 
adherent monocytes or B cells (211, 212). Part o f this difference in activation capacity 
may be attributed to the fact that for both CD4+ and CD8 + T cells EC preferentially 
activate memory T cells whereas professional APC can activate both naive and memory 
T cells (213-215). In vitro experiments suggest that naive T cells ignore and can even 
become anergized in response to antigens presented by endothelial cells (216-218). In 
contrast, co-cultures of memory T cells with allogeneic ECs show T cell cytokine 
production and proliferation, though even among memory CD4+ or CD8 + T cells the EC 
response is less compared to adherent monocytes (213). One reason for this difference 
may be that EC present a different, less immunogenic repertoire than professional APC
(187). Another part of the difference between EC and APC may lie in the distinct 
costimulatory signals provided by EC as compared to professional APCs.
T cell proliferation in response to EC is also dependent on costimulatory 
interactions between the T cell and the EC. However, unlike professional APC, most 
human EC do not express B7 molecules and consequently cannot activate nai've T cells to 
proliferate in allogeneic reactions. Mouse EC which do express B7.2 can activate CD8 +, 
but not CD4+, nai've T cells in vitro and in vivo (216, 219). As discussed previously, the 
costimulatory requirements of T cells change as T cells mature and differentiate. In 
particular, memory T cells require less costimulation than naive T cells (58, 59). Nai've T 
cells need the assistance of professional APC, like dendritic cells, to be activated, while 
memory T cells can be activated by less specialized (or “semi-professional”) APC such 
as EC. Early experiments suggested that the costimulatory capacity of EC appears to be 
contact dependent as paraformaldehyde-fixed cells were demonstrated to costimulate T
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cells (98, 197). Interestingly, EC also seems to be capable of providing costimulation in 
trans to cells such as fibroblasts that ordinarily cannot activate T cells (220, 221).
The costimulatory functions of EC were initially studied using polyclonal 
activators such as phytohemagglutinin (PHA) or anti-CD3 antibodies (98, 196, 222, 223). 
These studies demonstrated that EC like B lymphoblastoid cells could stimulate the 
transcription and secretion of both IL-2 and IFN-y from T cells whereas fibroblasts or 
smooth muscle cells could not. In examining the alloresponse, blocking interactions 
between CD2/LFA-3 partly inhibited proliferation whereas antibodies to ICAM-1/2, 
VCAM-1 or B7.1/2 had little effect on EC induced T cell proliferation despite having 
significant effects on allogeneic blood adherent cell induced proliferation (209, 213, 224, 
225). This suggests a strong role for the CD2/LFA-3 pathway in EC-mediated T cell 
activation. However, since blockade of the CD2/LFA-3 pathway did not completely 
inhibit cytokine production or proliferation (98, 197, 209) this suggests that other 
costimulators expressed by EC may play a role in mediating T cell activation.
The consequence of EC interactions with T cells is to generate specific changes in 
T cell signaling. ECs can trigger activity from the transcription factors AP-1, NFAT and 
NF-kB (226) as well increased the levels of AP-1 (227) in part due to LFA-3 dependent 
aggregation of lipid rafts (226). In addition to increasing mRNA of IL-2 and IFN-y in T 
cells, ECs can increase production o f IL-4 (223) and CD154 (228, 229) on the surface of 
T cells via LFA-3 dependent mRNA stabilization. CD4+ T cell adhesion, cytokine 
production in response to polyclonal activators and IL-2 mRNA stabilization depends 
upon signaling via OX40-OX40L (152, 153, 230, 231). The change in signaling leading 
to IL-2 synthesis mediated by EC appears to be cyclosporine resistant. This effect is EC-
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specific and cannot be replicated by B lymphoblastoid cells or blood adherent cells 
suggesting that EC provide a unique constellation o f costimulation (188, 197).
One caveat to studies done on costimulatory molecules are that T cell clones have 
even less costimulatory requirements than resting memory T cells and can often be 
stimulated by cells bearing peptide/MHC complexes without the assistance of 
costimulatory molecules. Many o f the studies done initially using EC as APCs utilized T 
cell clones (186, 232-234) and thus results interpreted from earlier studies may not truly 
assess costimulatory function of EC. Another important caveat is that there are 
significant species differences in the distribution of costimulatory molecules. For 
example, mice do not possess the gene for LFA-3 (CD58) and in fact do not display a 
known CD2 ligand on the surface of their EC (104, 235, 236). In addition, murine and 
porcine EC express B7.2. In humans, some early reports suggested that FIUVEC and 
some types o f microvascular EC express B7.2 (191, 237), however, since then several 
groups have shown by multiple methods that purified human EC populations largely do 
not express B7 molecules (219, 238, 239).
Unique features o f  antigen presentation by EC
EC-mediated T cell activation appears to provide signals that are distinct from 
other APCs. In comparison to B lymphoblastoid cells from the same donor, EC activate 
a smaller number o f both CD4+ and CD8 + T cells in an MLR or with superantigen (212, 
240). As discussed previously, EC also selectively activate memory but not naive T 
lymphocytes (214, 223, 240), There are several possibilities as to why EC are less
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efficient activators of T cells and cannot activate nai've T cells in comparison to 
conventional APC.
One possibility is that EC generate a different contact site compared to 
professional APC. T cells are known to form aggregates o f TCR, adhesion and 
costimulatory molecules at the contact site with professional APC known as the 
immunological synapse (33). Studies o f T cell-EC contact regions suggest that adhesion 
molecules at the T cell-EC synapse may be different from the one T cells form with 
professional APC (241, 242). Further evidence to support this comes from studies done 
using PHA in which EC can activate naive T cells (223). PHA is known to provide 
adhesion molecule-independent bridging between the T cell and the APC and thus with 
PHA EC can activate naive T cells whereas in the alloresponse or using other polyclonal 
activators like superantigen EC are limited to activating memory T cells (240). As 
mentioned previously, memory T cells also have elevated levels of |31 and p2 integrins as 
well as specialized chemokines receptors that may contribute to their capacity to be 
activated by EC (46, 243).
A second possibility is that EC may express molecules that actively inhibit T cell 
activation. Recent work has demonstrated that EC express a large amount of the 
inhibitory molecule PD-L1 and that this molecule is increased by IFN-y and TNF (194). 
Blockade of this interaction can increase T cell cytokine synthesis and proliferation in 
vitro (89, 194). EC have also been shown to express an activated form of TGF-P (244, 
245) which is known to have significant inhibitory effects on T cells (246). In addition to 
direct inhibitory effects on T cells, EC may also modulate regulatory T cell activity
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through the expression o f GITR-L (247) and IL- 6  (203) both of which have been 
demonstrated to decrease the suppressor function of regulatory T cells (248-251).
The final possibility is that EC do not express the appropriate costimulatory 
molecules and therefore provide less effective activation which would enable only a 
fraction of memory T cells and no naive T cells to reach the activation threshold. This is 
consistent with the idea that naive T cells have higher costimulatory requirements than 
memory T cells (58). As described above, EC do not express B7 molecules which are 
important costimulatory molecules in activating naive T cell (188, 189). However, EC do 
express other costimulatory molecules, notably LFA-3 as well as CD40, OX40L and 
ICOSL which are costimulators known to be important in T cell activation (124, 140, 
145,252, 253).
In addition to activating fewer T cells compared to professional APCs, EC- 
activated T cells also possess a distinct phenotype from those activated by conventional 
APCs. For instance, CD8 + T cells activated by EC retain expression of CD69, CD25 
and CD62L at 7 days, but have a lower level of perforin compared to CD8 + T cells 
activated by B lymphoblastoid cells (BLC) which upregulate then downregulate all three 
of these markers and express high levels of perforin (214). Additionally, allogeneic EC- 
activated CTL can kill both EC and BLC targets from the same donor, whereas BLC- 
activated CTL can only kill BLC, but not EC (215, 254). CD4+ T cells that have been 
activated by EC demonstrate a more rapid increase in CD 154 upon activation (228) and 
cyclosporine resistance (188).
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In vivo evidence fo r  EC antigen presentation
EC occupy a unique niche in that they are in continual contact with T cells in the 
periphery. As such, EC have a particular opportunity to influence the T cell response. T 
cells may encounter antigen presented on EC and recruit antigen-specific memory T cells 
to sites of infection. This is supported by the observation that intradermal injection of 
PPD antigen can elicit a response within hours in sensitized, but not naive test subjects 
(255). The rapid kinetics of this response suggests that EC may be presenting antigen to 
PPD-specific T cells and activating them in situ.
Further evidence for EC as APC in vivo comes from transplantation models. CTL 
specific for EC can be found in rejecting kidneys and heart transplants (256-258). 
Furthermore, depletion of passenger leukocytes using anti-CD45 monoclonal antibodies 
from human kidneys, which have MHC class II expressing EC, has no effect on allograft 
rejection (259), whereas in rats, whose EC do not express MHC class II, depletion of 
passenger leukocytes can significantly delay or prevent rejection (260, 261). 
Experiments done in mice also suggest the importance of EC antigen presentation in 
mediating transplant rejection. Kreisel et al showed in a model of cardiac allograft 
rejection that non-hematopoetic cells such as EC can mediate rejection by direct 
recognition of allogeneic MHC class I by naive CD8 + T cells. In this model, Kreisel et al 
used a bone marrow chimera where the donor bone marrow was syngeneic to the 
recipient and in this situation the cardiac allograft was still rejected indicating that 
rejection depended on MHC expressed by nonhematopoetic cells (262). In a model of 
skin rejection, CD8 + T cells could recognize the graft only when EC in the graft had been
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replaced by recipient EC demonstrating that EC can cross-present antigen and that EC 
alone can sufficiently activate T cells to mediate rejection (263). Another mouse model 
utilizing cardiac allografts showed CD4+ T cell allorecognition could also be mediated 
by EC. In this model, a TCR transgenic mouse specific for HY antigen presented on 
MHC class II molecules was transplanted with an HY positive heart bearing another 
MHC class II molecule and rejection only occurred when the donor heart was replaced by 
recipient EC (264). This suggests that like the case for CD8 + T cells, EC are also 
capable o f presenting antigen to CD4+ T cells as well though there is conflicting 
evidence. Unlike the previous experiment, experiments using bone marrow chimeras 
where the EC do or do not express MHC class II in a cardiac allograft show that MHC 
class II expression on EC, and therefore CD4+ T cell recognition o f EC, does not 
influence allograft rejection (216).
The final piece of evidence for EC presentation in vivo comes from another 
mouse model of diabetes. In this model, it was observed CD8 + T cells specific for 
insulin could cause diabetes in mice strains that had no preexisting inflammation. It was 
found that these T cells could recognize pancreatic endothelium in in vitro islet cultures. 
The recognition triggered T cell integrins and EC expression of chemokines, especially 
CCL21 or SLC, which mediated firm adhesion of the specific T cells to the endothelium 
(265). This suggests that antigen presentation by EC in addition to chemokine signaling 
may be important to in mediating appropriate T cell homing.
Thus, EC express molecules critical for antigen presentation including MHC 
molecules and costimulatory molecules. EC have also been demonstrated to activate 
both memory CD4+ and CD8 + T cells in vitro and in vivo, though this activation appears
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to be qualitatively and quantitatively distinct from activation mediated by other APCs 
such as BLC and monocytes. EC antigen presentation may have an important role in the 
homing to sites of inflammation and regulation of the local immune response.
1.4 MEMORY T CELLS IN TRANSPLANTATION
Identification o f  alloreactive memory T cells
Alloreactive memory T cells have been demonstrated to play a role in the 
rejection o f heart, kidney and liver transplants. This has been demonstrated by 
correlating the presence of pre-transplant memory T cells with increased incidence and 
severity of rejection (266-269). Furthermore, two groups have reported a correlation 
between pre-transplant frequency of alloreactive memory T cells as measured by in vitro 
IFN-y production to post-transplant risk of rejection (270, 271). Reduced numbers of 
pre-transplant memory T cells also correlated with improved function o f kidney allografts 
12 months following transplantation (270, 272). Late episodes of rejection in patients 2 
to 18 years after transplantation were also associated with an increase in cells with a 
memory phenotype (CD45RO+) in the circulation (273). In fact, several studies have 
shown that donor-reactive T cells with a memory phenotype can be generated in the 
presence of immunosuppression (271, 274). All these studies suggests that memory T 
cells may contribute to both initial and late acute rejection episodes. They also suggest 
that despite immunosuppression, existing memory T cells and those generated during 
early rejection episodes may contribute to late or chronic graft loss.
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Generation o f alloreactive memory T cells
Memory T cells, by definition, are T cells that have previously encountered 
antigen. In the case of allografts, the major source o f antigen exposure would be via 
pregnancy, blood transfusion or prior organ transplant. However, these situations do not 
apply to many patients which raises the question of how memory T cells arise in non­
sensitized patients. Two hypotheses for the generation o f this memory population are 
heterologous immunity and homeostatic proliferation.
Heterologous immunity refers to the concept that the T cells (or B cells) 
responding to one antigen may be cross-reactive with other related or unrelated antigens. 
This is applicable to transplantation in that T cells generated from infectious agents may 
be capable o f responding to alloantigen. This has been supported by work done in both 
mice and humans. Adams et al provided strong evidence that multiple viral infections 
were capable of generating significant numbers of alloreactive memory T cells that 
prevented the induction of tolerance (275). Memory CD8 + T cells that can react with 
alloantigen have also been found in mice infected with lymphocytic choriomeningitis 
virus (LCMV) (275). Memory CD4+ T cell cross reactivity with alloantigen was 
observed in mice infected by Leishmania major (276). Studies in humans have also 
correlated the presence of alloreactive cytotoxic T cells with seropositivity for Epstein 
Barr virus (EBV) and cytomegalovirus (CMV) (277, 278). Specifically, HLA-B8  
restricted CD8 + T cells specific for an EBV epitope showed cross reactivity with 
alloantigens, in particular HLA-B44 (277). Interestingly, prior to this study B 8  and B44 
were identified as an immunological pairing that predicted worse prognosis for allograft 
survival compared with pairings between other MHC haplotypes (279). Taken together,
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these studies provide significant evidence in humans to suggest that memory T cells 
generated by infection can respond to alloantigen and may contribute to allograft 
rejection.
Memory T cells may also be generated by the process known as homeostatic 
proliferation. Homeostatic proliferation refers to the observation that donor T cells 
undergo proliferation when transferred into lymphopenic recipients. This phenomenon 
has been well-documented in mice (280) and, as mentioned above, this lymphopenia- 
induced proliferation can generate T cells with a memory phenotype from naive T cells 
(44, 281, 282). Memory T cells generated in this fashion possess properties similar to 
antigen-experienced memory T cells; for instance, they can mediate rejection without 
secondary lymphoid organs (61). Homeostatic proliferation occurs naturally in neonates 
during the first wave of naive T cell release from the thymus into the empty lymphoid 
compartment (283). More relevant for transplantation, homeostatic proliferation can 
occur during infection (284), and following chemotherapy in older patients where the 
thymus has involuted (285). Another situation of lymphopenia relevant for 
transplantation is the use o f T-cell depletion strategies such as rabbit anti-human 
thymocyte globulin or anti-CD52 (286). Homeostatic proliferation following any of 
these situations to replenish the T cell pool may generate memory T cells that contribute 
to allograft rejection.
While alloreactive memory T cells can be generated from heterologous immunity 
and homeostatic proliferation, it is not clear that these mechanisms generate memory T 
cells that function like true antigen-specific memory T cells. More specifically, it is not 
known if the affinity and frequency of memory T cells generated by both these
31
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
mechanisms reflect properties of a true memory T cell response. Some studies suggest 
that homeostatically generated T cells are not as efficient at rejecting grafts compared 
with alloantigen experienced memory T cells (61). Studies of heterologous immunity 
have also suggested that the frequency o f alloreactive memory T cells generated by 
infection is lower than that seen with exposure to alloantigen (275, 276). However, the 
same studies also demonstrated that while the frequency of alloreactive memory T cells 
may be lower, rejection of a skin graft by cross-reactive memory T cells generated from 
infection had the same kinetics as second set rejection in mice that had previously been 
primed with donor-type alloantigens (276).
Memory T cells and inhibition o f  tolerance
In addition to contributing to increased episodes of allograft rejection and poorer 
long-term graft survival, memory T cells may also stymie the development of transplant 
tolerance. The quest to induce tolerance to foreign organ transplants has been the holy 
grail of the transplant field. A number of successful protocols have recently emerged in 
rodent models where recipients will tolerate donor organs indefinitely using combinations 
of costimulatory blockade (287-289). However, the same protocols in large animal and 
non-human primate models have been largely unsuccessful (290). One of the key 
differences between rodents and humans/large animals is the significant population of 
memory T cells in the circulation of the latter.
This idea of memory T cells being a barrier to tolerance has been tested in several 
rodent models. For instance, mice that have been sensitized to a donor antigen using a 
donor-type skin graft could reject a cardiac allograft in the presence of the anti-CD 154
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which induces tolerance in unsensitized mice (291-293). Memory T cells generated from 
infectious sources have also been shown to cause rejection even with a known tolerance 
inducing protocol (275). In those experiments, Adams et al showed that co-infection 
with LCMV, vaccinia virus, and vesicular stomatitis virus resulted in the generation of 
alloreactive memory T cells that prevented tolerance with a protocol involving treatment 
with CTLA-4Ig, anti-CD 154 mAh, busulfan and donor bone marrow infusion. That 
protocol has been demonstrated by several groups to induced donor-specific tolerance in 
nai've animals and Adams et al shows that the presence o f virally-specific CD8 + memory 
T cells prevented the induction of tolerance in the majority o f mice that had received the 
tolerance protocol.
Wu et al have also shown that memory T cells generated from homeostatic 
proliferation were similarly resistant to tolerance inducing protocols (281). Blockade of 
either CD28/B7, CD40/CD154 interactions or a combination of both agents which has 
been shown to induce tolerance in nai've animals was ineffective at preventing cardiac 
allograft rejection when homeostatically generated memory T cells were present. They 
further show that the mechanism for this graft rejection relied in part on a reduced 
necessity of memory T cells for CD28 costimulation.
The evidence discussed above highlights the importance of memory T cells in 
mediating allograft rejection and in particular how the unique properties of memory T 
cells can not only contribute to enhanced rejection responses, but also to prevention of 
tolerance. Transplant recipients more than likely have had numerous infections, 
particularly from EBV and CMV, and thus it is likely that any attempt to manipulate the
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immune response that focuses on T cell activation will need to account for memory T 
cells.
Targeting memory T cells
Current clinical therapies for organ transplants that generate global 
immunosuppression have revolutionized the success of organ transplantation. However, 
it is not clear what effects global immunosuppression has on T cell memory. Studies 
correlated pretransplant alloreactive memory T cells with acute rejection episodes that 
occurred despite immunosuppression using tacrolimus or sirolimus (270, 271). Memory 
T cells may also be resistant to lymphocyte depletion strategies using rabbit anti­
thymocyte globulin or anti-human CD52 mAb. A recent study from Pearl et al showed 
that memory CD4+ T cells are the dominant remaining subtype following depletion 
(286). The responses of these memory CD4+ T cells were resistant to steroids, 
deoxyspergualin, and sirolimus, but not tacrolimus or cyclosporin A. Other reports have 
indicated that memory T cells may be tolerized using a combination of deoxyspergualin 
and costimulation blockade (275) and that cyclosporine instead of inhibiting memory T 
cells actually promotes memory T cell formation and may result in an enhanced recall 
response (294, 295).
In addition to global immunosuppression, another strategy to target memory T 
cells is the induction of donor-specific tolerance. One study in mice showed that memory 
CD8 + T cells specific for hemagglutinin A (HA) were tolerized by administration of 
soluble HA peptide or via cross-presentation of antigen from pancreatic islets engineered 
to produce HA. Both methods seemed to produce tolerance via induction of peripheral
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apoptosis (296). Memory CD4+ T cells can also be anergized using by low avidity TCR 
stimulation (297). Memory T cells may also be subject to regulation from regulatory T 
cells. CD4+CD25+ T cells can suppress CD8 + memory T cells responses to Listeria 
monocytogenes and, when adoptively transferred, Tregs can also delay allograft rejection 
in a model of CD8 + T cell memory (298, 299).
Another strategy, and perhaps the one with the most promise, is to target memory 
T cell activation. Targeting the CD28/B7 and CD40/CD154 pathways has been 
demonstrated in numerous rodent models to successfully induce tolerance (288, 289, 300, 
301). However, memory T cells have been shown to be less reliant on APC mediated 
costimulation (58) and in particular they have a reduced requirement for CD28/B7 and no 
requirement for CD40/CD154 signaling (60). Despite being less reliant on CD28/B7 and 
CD40/CD154 singaling, it has become increasingly clear that memory T cells may 
depend on other costimulatory pathways to become fully activated. Some newly 
described pathways that have been implicated in memory T cell function include 
ICOS/ICOSL, 4-1BB/4-1BBL, OX40/OX40L, CD30/CD30L and CD27/CD70.
ICOS/ICOSL blockade has been shown to prolong allograft survival in rodents, 
particularly if administration of the blocking antibody is delayed suggesting that it 
interferes with effects that occur after T cells have been primed (302). Blocking ICOS- 
ICOSL interaction has also been shown to prevent chronic rejection and potentiate 
tolerance when combined with other immunosuppressive treatments (303). 4-1BB/4- 
1BBL has been demonstrated in murine models to be important in CD 8 + T cells 
mediated rejection o f allogeneic intestine (304), cardiac (305), and skin (305) allografts. 
Blockade of 4-1BB/4-1BBL pathway prolonged graft survival for all organs by
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decreasing the number of alloreactive CTL, however blockade did not induced tolerance 
to grafts in any of these models. Despite success in inhibiting nai've T cells responses, 
inhibition of 4 -IBB did not prolong graft survival in a murine model o f memory T cell 
mediated skin allograft rejection (306). OX40-OX40L interactions have been shown to 
be important in CD4+ memory T cell responses to allografts (307). In this rat model of 
transplant rejection, blockade of OX40-OX40L in combination with B7 blockade 
prolonged cardiac allograft survival in recipients receiving primed T cells (307). Vu et al 
also showed that OX40-OX40L blockade in conjunction with B7 and CD40/CD154 
blockade could induce long term survival of skin grafts in mice possessing memory T 
cells that were generated by either donor-specific priming or homeostatic proliferation 
(306). Finally, targeting CD27-CD70 interactions could lead to indefinite allograft 
survival in the presence o f memory CD8 + T cells (308). All the above evidence suggests 
that memory T cells do require costimulation distinct from nai've T cells to achieve full 
activation and that targeting these costimulatory pathways can affect the response of 
memory T cells to allografts though the specific mechanisms by which they work remain 
unclear.
Memory models and the SCID/beige mouse-human skin chimeric transplant model
Murine models of T cell memory have contributed significantly to our 
understanding of memory and allograft rejection. The existence of allospecific memory 
T cells in vivo was initially suggested using a murine minor Ag (HY) model confirmed 
that allosensitized memory T cells mediate an accelerated form of rejection known as 
second set rejection (309). Since that time, murine models have shown that allospecific
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memory T cells can be generated by heterologous immunity or homeostatic proliferation 
can mediate transplant rejection (275, 281). These murine models using presensitized 
mice or mice with homeostatically generated memory T cells demonstrated that memory 
T cell mediated rejection is independent of secondary lymphoid organs (61) and resistant 
to CD28 and CD 154 blockade (281, 291, 292, 306). However, studying memory in 
transplantation remains limited by fact that mice used in these models are either too 
young or too antigen inexperienced to have significant populations of memory T cells. 
Almost all o f the current mouse models used to study memory must generate memory T 
cells through specific infection or donor-specific priming which may not accurately 
recapitulate the numbers and diversity found in large animals and humans. As mentioned 
above, this in part may explain why protocols developed in mice for tolerance have not 
been successfully translated into large animals or humans. Therefore, one strategy to 
improve our understanding of memory may be to study the human immune response and 
one method to do so in vivo is the human mouse chimera model.
The ability to study a functional human immune system in an in vivo model was 
made possible by the development o f immunodeficient mouse hosts. Mice bearing the 
severe combined immunodeficiency (SCID) mutation or lacking recombinase activating 
gene (RAG) have been successfully used as hosts for human cells. In the absence of 
mouse T and B cells, stable long-lived reconstitution of human T cells can be achieved 
with interperitoneal injection o f human peripheral blood leukocytes in the SCID mouse 
(310). These mice have been used to study the human immune system in particularly in 
HIV and transplantation. Early studies demonstrated that skin could be engrafted onto 
SCID mice and that if  these mice were reconstituted with human T cells that the
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recruitment o f these T cells are limited to human tissue and that this recruitment depends 
on specific cytokines (179, 311). In addition to mediating allograft rejection, studies 
using tetanus toxin demonstrated that human T cells derived from the mouse spleen could 
be activated in vitro which indicated that the human T cells retained function in their 
murine hosts (312). Furthermore, T cells from human donors immunized with tetanus 
toxin, but not naive donors, homed specifically to the human skin graft when tetanus 
toxin was injected into the skin graft, but not when it was injected into the adjacent 
mouse skin suggesting that recruitment depended on a human microenvironment.
The model used in our laboratory employs SCID/beige mice which have an 
additional mutation in a lysosomal transporter that is homologous to the Chediak-Higashi 
gene found in humans (313). The effect of this gene is to effectively eliminate NK cell 
function in the mice, which is to ensure human graft acceptance by preventing xenograft 
recognition by murine NK cells. The protocol developed by Murray et al involves 
grafting SCID/beige mice with human skin allowing the skin to heal in for several weeks 
and then adoptively transferring PBMC allogeneic to the skin into the peritoneal cavity of 
the mice (179). CD3+ T cells can be detected in the circulation within one week and no 
significant levels of CD19+ B cells, CD14+ macrophages, or CD16+ NK cells can be 
detected in the circulation. Human B and T cells can be found in the lymph nodes in low 
numbers and while the mice do produce circulating human immunoglobulin there is no 
evidence of complement deposition or neutrophil invasion (314). Depletion of B cells 
also has no effect on the infiltration or microvascular destruction observed in the 
transplanted human skin grafts (315). Graft versus host disease is also negligible in this 
model because the human antibodies produced do not appear to be specific for murine
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antigens and the MHC restriction between mice and humans is sufficiently different to 
prevent direct recognition. There is also no evidence of human macrophage or dendritic 
cell engraftment (314). Thus, this model describes a largely T cell mediated allograft 
response.
The initial studies of this model characterizing the response demonstrated that this 
model recapitulates first set skin rejection observed in humans (179). Human skin grafts 
on mice reconstituted with allogeneic PBMC demonstrate progressive leukocyte 
infiltration and destruction of the microvasculature that has equivalent kinetics and 
histologic appearance to human allogeneic skin rejection. Experiments showing 
significant graft protection using mouse anti-LFA-3 mAb or human LFA-3-IgGl fusion 
protein have demonstrated the utility of using this model to study human allograft 
rejection in vivo (109). Expansion of this model to human arteries has also demonstrated 
successful engraftment and further supports the use of this model to study human 
alloresponses (316, 317).
1.5 THESIS OBJECTIVES
The basis for the studies in this thesis derives from three observations. First, 
memory T cells are a significant hindrance to allograft rejection and long-term allograft 
survival (318). Second, EC antigen presentation has been shown to play an important 
role in transplant rejection (197, 263, 264). Third, EC have been shown to selectively 
activate memory T cells (213, 214) through LFA-3 and other as yet unknown 
costimulatory molecules expressed on EC (197). The questions of how EC activate
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memory T cells and what role this activation may play in transplant rejection have not 
been explored.
Thus, I hypothesize that EC express molecules that uniquely enable them to activate 
memory T cells and that presentation o f antigen by EC using these costimulatory 
molecules contributes to memory T cell mediated allograft rejection. In this thesis, I 
address this question with the following four aims. First, I will detail the human memory 
T cell response to human EC in vitro and describe an in vivo model to study human 
memory T cell mediated allograft rejection (Chapter 3). Second, using this model, I will 
investigate the role o f B7 costimulatory molecules on EC-mediated T cell activation in 
vitro and in vivo using a novel CD28 blocking reagent (Chapter 4). Third, I will examine 
the role of memory T cell specific costimulators on EC-mediated T cell activation in vitro 
and in vivo (Chapter 5). Finally, I will study the response of different memory T cell 
subsets to EC (Chapter 6 ). Completion o f these aims will enhance the understanding of 
how EC activate memory T cells and elucidate the role that interactions between EC and 
memory T cells play in allograft rejection.
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CHAPTER II -  MATERIALS AND METHODS
2.1 MATERIALS
Cytokines
Recombinant human TNF (TNFa) was purchased from R&D Systems 
(Minneapolis, MN) and recombinant human IFN-y from Biosource International 
(Camarillo, CA).
Antibodies
Mouse anti-human CD4, CD8 , CD80, and CD8 6  conjugated to phycoerythrin 
were obtained from BD Biosciences (San Jose, CA). Azide-free IgGl was obtained from 
eBioscience (San Diego, CA) and mouse anti-human CD58 (LFA-3) (clone TS2.9) was 
purchased from Pierce Biotechnology (Rockford, IL). Mouse anti-CD28 (clone 28.2) and 
CD27 (clone M-T271) were purchased from BD Bioscience (San Jose, CA). Mouse 
anti-human 4 -IBB and mouse anti-human OX-40 mAbs were purchased from Ancell 
(Bayport, MN). Mouse anti-human ICOS mAb was purchased from eBioscience (San 
Diego, CA). Mouse anti-human 4-1BBL mAb was a gift from X.G. Zhang (Suzhou, 
China), mouse anti-human ICOSL mAb was a gift from H.W. Mages (Berlin, Germany). 
Mouse anti-human OX40L mAb and recombinant human 4-lBBFc were purchased from 
R&D Systems (Minneapolis, MN). Biotin-conjugated goat and donkey anti-mouse 
antibodies were purchased from Jackson ImmunoResearch (West Grove, PA).
FK734 was produced by Fujisawa Pharmaceutical Co., Ltd. (now Astellas Pharma 
Inc.). FK734 is a humanized IgG2ic anti-human CD28 antibody that has the 
complementary determining regions (CDRs) of the mouse anti-human monoclonal 
antibody TN228 (319) and the Fc domain of human IgG2M3, in which 2 amino acid
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mutations (V234A, G237A) have been introduced into the human y2 chain to eliminate 
binding of the antibody to FcyR. The original TN228 cell line was generated by 
immunizing BALB/c mice with human CD28-transfected mouse fibroblast L cells and 
fusing immune splenocytes with P3 U1 myeloma cells. The purified molecule consists of 
two heavy chains and two light chains, which are 447 amino acid residues 
(C2177H3358N 575O669S19; M W  48898.64) and 218 amino acid residues 
(C 1043H 1628N279O342S7 ; M W  23772.21) in length, respectively. FK734 binds to a human 
CD28-mouse IgG Fc fusion protein (Kd=3.72xl08) and inhibits proliferation of human T 
cells stimulated with anti-CD3 and P815/human CD80+ cells in a concentration 
dependent manner with the half inhibitory concentration at 74.6 ng/mL (unpublished 
data, K.K.). FK734 does not cross-react with mouse CD28.
2.2 IN  VITRO  METHODS
Isolation and culture o f  human cells
All human cells and tissues were obtained under protocols approved by the Yale 
Human Investigations Committee. PBMCs were isolated from by density gradient 
centrifugation of leukapharesis products from healthy adult volunteers by using 
Lymphocyte Separation Medium (Gibco BRL, Grand Island, N.Y.). Isolated cells were 
stored in 10% DMSO/90% FBS in liquid N 2 (-196°C) and were thawed and washed 
before use (320). CD4+ and CD8 + T cells were isolated from PBMCs by positive 
selection by using Dynabeads (Dynal (now Invitrogen), Lake Success, N.Y.) as described 
previously (189). The selected populations obtained by this procedure were routinely 
>97% CD4+ or CD8 + by FACS analysis (data not shown). Activated T cells were
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removed by negative selection with an anti-HLA-DR antibody at a concentration o f 5 
pg/ml (LB3.1; gift of J. Strominger, Harvard University, Cambridge, Mass.) for 20 min, 
washing twice, and depleting by using magnetic beads conjugated to goat anti-mouse 
antibody (Dynal). Naive and memory subsets of T cells were isolated from the total T cell 
population by further negative selection by using anti-CD45RA or anti-CD45RO 
antibodies at a concentration o f 2 pg/ml (Biosource, Camarillo, Calif.). To obtain 
memory T cell subsets, CD4+ T cells were isolated from PBMCs by positive selection by 
using BD IMag CD4+ magnetic particles (BD Biosciences, San Jose, CA). The selected 
population obtained by this procedure was routinely >95% CD4+ by flow cytometry (data 
not shown). Cells were then stained with mouse antibodies to mouse anti-human CD62L 
(BD Biosciences San Jose, CA), mouse anti-human CD45RO (BD Biosciences, San Jose, 
CA) and mouse anti-human CCR7 (R&D Systems, Minneapolis, MN) and subjected to 
FACS sorting on a FACSAria (BD Biosciences, San Jose, CA) to isolate Tcm 
(CD45RO+, CCR7+ and CD62L+) from TEM (CD45RO+, CCR7-, CD62L-).
Monocytes (Mo) were obtained by incubating PBMCs on gelatin-coated tissue 
culture plates in RPMI 1640 medium containing 10% FCS, 100 units/ml penicillin, 100 
pg/ml streptomycin, and 2 mmol/liter L-glutamine (RPMI/FBS) for 1 hour then washing 
away the non-adherent cells. Mo were then harvested by washing the plates with PBS 
and incubating the flasks with ice-cold 10 mM EDTA in RPMI 1640 for approximately
5-10 minutes. Detached cells were then collected, centrifuged at 1200 rpm and plated 
onto 24-well gelatin-coated plates in RPMI/FBS. The selected population obtained by 
this procedure was routinely >80% CD 14+ by FACS analysis and <10% CD3+ (data not 
shown). Alternatively Mo were negatively selected using the Monocyte Negative
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Isolation kit from Dynal (Lake Success, NY). Whole PBMC were incubated with the 
blocking and antibody reagents for 15 minutes at 4°C and then washed with PBS/0.5% 
BSA/2 mM EDTA. The cells were then incubated with the supplied beads at the ratio 
recommended by the manufacturer. The bead/cell mixture was then incubated at 4°C for 
15 minutes and then placed on the magnet. The cells left in the supernatant were then 
harvested for use. The population obtained by this procedure was routinely >90% 
CD 14+ by FACS analysis and <5% CD3+ (data not shown).
HUVECs, which are uniformly positive for CD31 and negative for CD45 by 
FACS analysis, were isolated and cultured as described previously (321). CD86-
transduced FIUVEC were generated using a retroviral vector containing the full-length 
mRNA of human CD86 using methods described previously (322). Transduced EC, 
control EC (EC transduced with retroviral vector containing LacZ or EGFP), and Mo 
expression of CD80 and CD86 were compared by staining cells with mouse anti-human 
CD80 and CD86 and subjected to FACS analysis (Figure 4.3s). Human dermal 
microvascular endothelial cells (HDMEC) were isolated from discarded human skin, 
purified using anti-CD31 mini MACS beads (Miltenyi Biotec, Auburn, CA) and cultured 
in EGM2-MV growth medium (Clonetics, San Diego, CA) as previously described (323). 
When indicated, the cells were treated with 50 ng of IFN-'f per ml for 3 days prior to 
cocultivation. After pretreatment with IFN-7, the ECs were uniformly HLA-DR positive 
(data not shown).
Monocyte (Mo) and HUVEC co-cultures with allogeneic T cells
44
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
For the co-cultures, 1.5x10s HUVEC or HDMEC at subculture level 1 or 2 were 
plated into gelatin-coated wells of a 24-well culture plates (Falcon, Becton Dickinson, 
Bedford, MA) and grown to visual confluence. EC cultures were treated with 50 ng/mL 
of IFN-y (Biosource, Camarillo, CA) per ml for 3 days prior to the addition o f T cells. 
After pretreatment with IFN-y, the ECs were uniformly HLA-DR positive by FACS 
analysis (data not shown). 1x10s Mo were collected and plated into gelatin-coated wells 
o f a 24-well culture plates and cultured for three days in RPMI/FBS. Purified T cell 
pupulations were then added to each well (~ lx l0 6 per well) (See Figure 2.1). All 
cultures were maintained in 5% CO2 at 37°C. The medium for co-culture consisted of 
RPMI 1640 supplemented with 10% FBS serum (Gibco BRL, Grand Island, N.Y.), 2 mM 
L-glutamine, 100 U/ml penicillin, and 100 pg/ml streptomycin.
For cell surface immunostaining, T cells from co-cultures were collected by 
washing wells twice with Hanks-buffered saline solution (HBSS) and centrifugation at 
1000 x g  for 5 min, washed twice with ice-cold PBS containing 1% bovine serum 
albumin and 0.1% sodium azide (PBS/BSA). T cells were then incubated with the 
indicated antibodies or isotype controls at 2 ug/ml in PBS/BSA for 2 h at 4°C and then 
analyzed using a FACSort and Cellquest software (BD Biosciences). To measure 
proliferation by carboxy-fluorescein diacetate succinimidyl ester (CFSE) dilution, the T 
cells were stained with 250 nM CFSE (Molecular Probes, Eugene, OR) for 15 min prior 
to co-culture with ECs. Cells were collected after the indicated times and subjected to 
FACS analysis.
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Treat with IFN-gamma for 3 days Add positively isolated T cells







Figure 2.1. E C -T  cell co-cultures. For co-cultures with CD4+ T cells, EC are treated with 
IFN-y for three days to upregulate MHC class II. T cells are then added to the EC. After 24h 
supernatants are collected for analysis o f  cytokine production by ELISA. T cells are then either 
subject to FACS or radiolabeled thymidine to analyze their proliferation.
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Preparation o f RNA, cDNA, and Procedure fo r  Quantitative PCR
RNA was isolated from T cells and EC using RNeasy mini kits (Qiagen, Valencia, 
CA) with on-column DNase treatment following the manufacturer's supplied instructions. 
RNA was isolated from skin grafts using the RNeasy fibrous tissue mini kit (Qiagen) 
again with on-column DNase treatment and following the manufacturer’s supplied 
instructions. cDNA was synthesized using Taqman RT reagents (Applied Biosystems), 
following the manufacturer's instructions. Quantitative real-time PCR (qRT-PCR) for 4- 
1BBL, ICOSL, OX40L, FasL, Granzyme B and Perforin and CD3s was performed as 
using primers shown in Table 1-2. The PCR reaction mixture (final volume 25 pi) 
contained 5 pi of cDNA, 1 pi of 10 pM forward primer, 1 pi of 10 pM reverse primer, 2.5 
pi of PCR lOx SYBR Green PCR buffer, 3 pi o f 25mM MgCl2, 2 pi of dNTP mix (2.5 u im  
dATP, 2.5 mM dCTP, 2.5 mM dGTP, and 5 mM dUTP), 0.125 pi o f AmpliTag Gold DNA 
polymerase (5 units/pl AmpliTag Gold DNA polymerase), and 10.375 pi of H20 . The 
PCR reaction was performed in triplicate (3 wells of C96 well plate). The reaction was 
amplified with iCycler iQ Multicolor Real Time PCR Detector (Bio-Rad) for 37 cycles 
with melting at 94 °C for 30 s, an annealing at 58 °C for 30 s, and extension at 72 °C for 1 
min in iCycler iQ PCR 96-well plates (Bio-Rad). Samples were analyzed by generating a 
standard curve from plasmids containing the PCR fragment and expressed as copy 
number where indicated or by calculating a fold induction. The relative quantification 
values for the gene expression was calculated from the accurate Ct, which is the PCR 
cycle at which an increase in reporter fluorescence from SYBR Green dye can be first 
detected obtained above a baseline signal. C t values for GAPDH (or CD3s) cDNA were 
subtracted from CT values for the cDNA of the gene of interest for each well to calculate
47
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
A-C t. The triplicate a -C | values for each sample were averaged. To calculate the fold 
induction of mRNA in experimental cells compared with control cells, the averaged A-C t 
values calculated for control cells was subtracted from A-CT values calculated for 
experimental cells to calculate AA-Cj. Then, the fold induction for each well was 
calculated by using formula. The fold induction value for triplicate wells was
averaged, and data are presented as the mean ± S.E. of triplicate wells.
Flow cytometric analysis
For cell surface immunostaining, HDMEC/HUVEC were washed twice with 
Hanks-buffered saline solution (HBSS) and incubated with trypsin/EDTA for 1 min. 
Detached cells were collected by centrifugation at 1000 x g  for 5 min, washed twice with 
ice-cold PBS containing 1% bovine serum albumin and 0.1% sodium azide (PBS/BSA). 
Either detached cells, monocytes or T cells were then incubated with the antibodies or 
isotype controls at 2 pg/ml in PBS/BSA for 2 h at 4°C. After two further washes cells 
were incubated with 2 pg/ml biotin-conjugated secondary antibodies in PBS/BSA for 1 h 
at 4 °C. Following another two washes, cells were incubated with 1 pg/mL strepavidin-R 
phycoerythrin (Molecular Probes, Eugene, OR) in PBS/BSA for 30 minutes at 4°C, 
washed a further two times and analyzed on a FACSort using Cellquest software (BD 
Biosciences).
ELISA
Supernatants were collected from co-cultures of T cells with HUVEC or with Mo 
after 24h or 48h of co-culture. The samples were then assessed using an ELISA kit for
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IFN-y (Biosource, Camarillo, CA) or IL-2 (Ebioscience, San Diego, CA). Both ELISAs 
were performed as described by the respective manufacturers.
Proliferation Assays
T cell proliferation was measured by [3H]-thymidine incorporation. In brief, 
HDMEC or HUVEC were cultured in 96-well U bottom plates (Falcon) as described 
previously (323) and confluent monolayers were then pretreated with 50 ng IFN-y 
(Biosource, Camarillo, CA) prior to co-culture with CD4+ T cells. All HUVEC were 
then treated with mitomycin C (50 pg/ml in PBS, 30 min; Sigma-Aldrich, St. Louis, MO) 
prior to co-culture to prevent their proliferation as described previously (209). 24h prior 
to each indicated time point, 1 pCi [3H]-thymidine (Amersham, Arlington Heights, IN) 
was added to each well. Plates were frozen, thawed and then harvested on a 96-well 
harvester (Tomtec, Hamden, CT) and counted on a Microbeta scintillation counter 
(Wallac, Gaithersburg, MD). The mean of the replicates (n=16) was calculated, and the 
mean [JH]-thymidine incorporation into wells containing only EC was subtracted.
To measure proliferation by carboxy-fluorescein diacetate succinimidyl ester 
(CFSE) dilution, the cells were stained with 250 nM CFSE (Molecular Probes, Eugene, 
Oreg.) for 15 min prior to coculture with ECs. Cells were then collected after co-culture 
and subjected to FACS analysis.
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2.3 IN  VIVO  METHODS
Animals
C.B-17 SCID/beige female mice (Taconic Farms, Germantown, NY) were used at 
5-8 wk o f age. All protocols involving animals were approved by the Yale Animal Care 
and Use Committee. The animals were housed individually in microisolator cages and 
were fed autoclaved food and water. Prior to each experiment, serum mouse IgG levels 
were determined by sandwich ELISA using reagents from Cappel (Durham, NC) as 
previously described (179). SCID/beige animals were considered "leaky" at IgG levels >1 
jig/mland excluded from experimental use.
Skin Grafting
Human skin was obtained from cadaveric donors through the Yale University 
Skin Bank under a protocol approved by the Yale Human Investigations Committee. 
Human skin was orthotopically transplanted to SCID/beige mice as previously described 
(179). In brief, 0.5-mm-thick sheets were divided into 1-cm2 pieces, kept at 4°C in RPMI 
1640 medium (GIBCO/BRL) and fixed onto similar sized defects on the dorsum of C.B- 
17 SCID/beige recipients using staples (3M, St. Paul, MN). The resultant surface area of 
healed grafts was kept constant between animals when possible. The skin reproducibly 
grafted with a >95% success rate and was allowed to heal for 4 wks before manipulating 
the graft. Rare animals that did not successfully engraft were excluded from the 
experimental groups before treatments.
PBMC and T cell subset adoptive transfer
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For adoptive transfer of PBMC, SCID/beige mice were reconstituted with 3 x 108 
human PBMC by i.p. inoculation 4-5 weeks after skin engraftment. Animals 
demonstrated no signs o f graft-vs.-host disease. Rare animals that failed to reconstitute 
with human T cells were, by prior design, excluded from analysis.
For memory or nai've T cell subsets, CD45RA+ or CD45RO+ T cells were 
isolated as described above and cells were >95% pure populations and both populations 
contained approximately a 2:3 ratio of CD8+ to CD4+ cells. SCID/beige mice were 
reconstituted with 3 x 108 human PBMC by i.p. inoculation 4 wk after skin engraftment. 
Animals demonstrated no signs of graft-vs.-host disease. Rare animals that failed to 
reconstitute with human T cells were, by prior design, excluded from analysis. 
Alternatively, separated nai've or memory T cells were then counted using a Coulter 
particle counter (Beckman Coulter, Fullerton, CA) and 1.5 x 108 cells were i.p. 
inoculated into SCID/beige mice 4 weeks after skin engraftment.
For memory T cell subsets, CD62L-CCR7- ( T e m )  or CD62L+CCR7+ ( T c m )  T 
cells were isolated as described above and the resulting cells were >95% pure upon 
reanalysis. SCID/beige mice bearing human skin from a donor allograft to the PBMC 
were adoptively transferred with 1 x 106 cells from either subset by tail vein injection 4 
wk after skin engraftment. None of the animals demonstrated signs of graft-vs.-host 
disease.
Circulating human T cells were evaluated by flow cytometry as previously 
described (320). In brief, heparinized retro-orbital venous samples were obtained 14 days 
after reconstitution, and the erythrocytes were lysed. The leukocytes were incubated with
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FITC-conjugated mouse anti-human CD3 (Immunotech, Westbrook, ME) and PE- 
conjugated rat anti-mouse CD45 (Sigma-Aldrich, St. Louis, MO) mAbs. Samples were 
then analyzed using a FACSort (BD Biosciences, San Jose, CA). (See Figure 2.2)
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Figure 2.2 The human-SCID mouse chimera. SCID/beige mice are grafted with split thickness human skin. The grafts are 
allowed to heal for 4-6 weeks. The mice are then injected with either CD45RA+ or CD45RO+ T cells (A), blocking antibodies 
and PBMC (B), or purified central or effector memory T cells (C). The grafts are then harvested and taken for analysis.
H&E - DwmpMfietogy Evaluation
Histology and Immunohistochemistry
Human skin grafts, harvested at indicated times, were processed for paraffin- 
embedded or frozen sections as previously described (320). The degree of graft 
microvascular damage was evaluated from H&E-stained sections by a dermatopathologist 
(J.M.M.) blinded to treatment protocols as previously described (109). In brief, the 
percentage of dermal vessels showing injury, defined as EC loss or sloughing, and 
thrombosis were assessed from an average o f three high-power (x200) fields using the 
following semiquantitative grading scale: grade 0, all vessels patent and uninvolved; 
grade 1, <25% of vessels show injury; grade 2, -'50% of vessels show injury; and grade 3, 
>75% of vessels show injury.
Immunostaining was performed using isotype-matched, nonbinding control Abs 
or the following Abs: mouse anti-human CD3 (PS1, IgG l) and mouse anti-human CD31 
(HC1/6, IgG l) (Novocastra Ltd., Newcastle Upon Tyne, UK). The number of human 
CD3+ T cell infiltrates and CD31+ vessels were assessed by counting and averaging the 
number o f T cells/complete lumens in 10 random, 40x high-power fields (HPF) using the 
ImageJ program (NIH).
Preparation o f  RNA, cDNA, and Procedure fo r  Quantitative PCR
RNA was isolated from skin grafts using the RNeasy fibrous tissue mini kit 
(Qiagen, Valencia, CA) again with on-column DNase treatment and following the 
manufacturer’s supplied instructions. Quantitative real-time PCR (qRT-PCR) was 
performed exactly as described above, using primers shown in Table 1-3. Samples were
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either analyzed by examining threshold cycles and comparing threshold cycles between 
the two groups using a one-tailed t-test with a Bonferroni correction or by calculating the 
amount of mRNA from a standard curve and expressing it as ± S.E.
Statistics
Statistical differences between groups with respect to T cell infiltrates were evaluated 
using a two-tailed t-test. Statistical difference between the pathology scores were 
evaluated using a nonparametric analysis Mann-Whitney U test. [ H]-thymidine analysis 
was done with a two-tailed t-test.
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Target Primers (5,_^3’)
4-1BBL ACTGCCC AGCT GGT AC ATTC 
CACAGGTCCTTTGTCCACCT
ICOSL AAACCTTGCAGGCAACAATC 
C ACTT GGCTT GGAT C AGT C A













T CC AG AGGTT G AGC A A ATT A




Table 1-2. PC R prim ers used fo r  studies.
Each primer is listed 5' -43'. The forward primer is above and the reverse primer below. 
In each case, the identity of the amplified fragment was confirmed by sequencing.
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CHAPTER III -  IN VITRO AND IN VIVO STUDY OF MEMORY 
AND NAIVE T CELL RESPONSES TO THE ENDOTHELIUM
3.1 INTRODUCTION
Long-lived memory T cells may play an important role in early events following 
transplantation. Alloreactive memory T cell populations are not typically present in the 
young rodents commonly used to study transplantation. However, in adult humans, about 
one half o f the T cells capable of responding to allogeneic cells in limiting dilution assays 
express CD45RO, a marker o f memory cells (209, 324). However, there is no direct 
evidence that human memory T cells, like their murine counterparts, can mediate 
rejection.
Memory T cells also have a special relationship to vascular endothelial cells (EC). 
Central memory T cells express chemokine receptors (e.g. CCR7) and adhesion 
molecules (e.g. CD62L) that preferentially interact with high endothelial venules (46). 
Effector memory cells express chemokine receptors like CXCR3 that respond to 
inflammatory chemokines and express high levels of adhesion molecules (e.g. LFA-1 or 
VLA-4) (325) whose ligands are preferentially expressed by cytokine-activated 
peripheral vascular EC (200). This phenotype allows effector memory cells to be directly 
recruited to sites o f peripheral inflammatory reactions such as allograft rejection. 
Furthermore, resting memory T cells can be activated by alloantigens presented by EC 
but not other stromal or parenchymal cells in vitro (206, 213).
It has become increasingly evident that T cell memory may pose a significant 
challenge to transplantation. Memory T cells specific for and expanded by microbial Ag, 
like nai've T cells, may cross-react with allogeneic MHC-peptide complexes with very 
high frequency (275). Recent evidence has suggested that the number of cross-reactive
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anti-donor memory T cells correlates with increasing rejection rates (271) and may 
prevent the ability to achieve tolerance (291). This phenomenon has largely been 
overlooked in the past because alloreactive memory T cell populations are not typically 
present in the young rodents commonly used to study transplantation. However, adoptive 
transfer o f memory T cells in rodents can rapidly reject a cardiac graft in the absence of 
secondary lymphoid organs whereas transfer o f naive T cells cannot (61). I have 
developed a model in which I can test the capacity o f human memory T cells to mediate 
allograft rejection (179, 314). Specifically, I engraft C.B-17 SCID/beige mice with split 
thickness human skin, containing the superficial vascular plexus o f the papillary dermis. 
The healed graft is perfused through retained human EC-lined microvessels. At this 
point, usually 3-4 weeks post-skin transplantation, I adoptively transfer human allogeneic 
PBMC or nai've or memory T cell subpopulations by i.p. inoculation. Within seven days, 
human T cells are present in the mouse circulation and by 12-14 days infiltrate the human 
graft. Between 14-21 days, human graft EC are progressively destroyed and the graft 
frequently ulcerates, indicative of rejection. Previous studies have shown that this 
response depends upon LFA-3 (109).
The data in this chapter demonstrate memory, but not naive T cells can proliferate 
in response to microvascular EC derived from human skin. I also use the chimeric 
human-SCID mouse model described above to show that the graft EC injury is mediated 
by human memory but not naive T cells.
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3.2 RESULTS
HDMEC activate memory but not naive T cells
Cultured HUVEC have been shown to preferentially activate allogeneic memory 
T cells compared to naive T cells and they do so in an MHC and costimulation dependent 
manner (209, 223). Cultured HUVEC are the most widely used model of human EC, but 
the behaviors o f microvascular EC, the targets of graft injury, are not always reflected 
accurately by this cell type. I therefore began my study by examining the capacity of EC 
isolated from human skin microvessels (i.e. HDMEC) to activate memory and naive T 
cells in co-culture. Cultured HDMEC, like HUVEC, express HLA-A/B but not HLA-DR 
and increase expression o f both type of molecules in response to IFNy (326). In my 
experiments, HDMEC were treated with IFN-y for 3 days (to induce HLA-DR) for 
optimal CD4+ T cell stimulation and then co-cultured with allogeneic, CFSE-labeled T 
cell subsets. Media were collected at 24h for measurement of cytokines and T cells were 
collected after 7 days for analysis o f proliferation. These time points were judged 
optimal in pilot experiments. Significant production of both IFN-y and IL-2 was 
observed in co-cultures containing memory but not nai've T cells (Figure 3.1 A). By 
FACS analysis purified memory (CD45RO+) T cells, but not naive (CD45RO-) T cells, 
proliferated in co-culture with HDMEC (Figure 3 .IB). When further separated into 
CD4+ and CD8+ memory and naive cells, again memory cells, but not nai've cells 
proliferated in response to HDMEC (Figure 3.1C). In control experiments CD4+ T cells 
did not respond to HDMEC that were not pretreated with IFN-y (data not shown). Thus, 
HDMEC, like HUVEC, selectively activate allogeneic memory T cells and require pre­
treatment with IFNy to stimulate CD4+ T cells.
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Figure 3.1. HDMEC activate memory T cells.
HDMEC were treated with IFN-g to upregulate 
MHC class I/II and subsequently co-cultured 
with either nai've (CD45RA+) or memory 
(CD45RO+) T cells, (a) Media was taken for 
ELISA from HDMEC cultured with either na­
ive or memory T cells for 24 hours. Memory 
T cells cultured with HDMEC showed signifi­
cant production of both IFN-g and IL-2 
(jhatched bars) when compared to nai've T cells 
(black bars), (b) After one week of co­
culture, CFSE-labeled T cells were stained 
with anti-CD3 and subjected to FACS analysis. 
Memory T cells demonstrated significant pro­
liferation (4.51%, right panel, upper left quad­
rant, circled population), whereas nai've T cells 
showed very little proliferation (0.49%, left 
panel, upper left quadrant, circled population) 
as judged by CFSE dilution, (c) Following one 
week o f co-culture, purified and CFSE-labeled 
CD4+ or CD8+ nai've and memory T cells 
were stained with CD4 or CD8, respectively, 
and analyzed using FACS. Again, purified 
memory T cells (left panels, upper left quad­
rants, circled population)) or either subset 
showed significantly greater proliferation than 
their purified nai've counterparts (right panels, 
upper left quadrants, circled population). The 
data shown represent one of four experiments 
with similar results.
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Memory T cells cause human skin allograft rejection in human PBL-SCID
I have previously described a model o f human T cell responses to allogeneic skin 
microvascular EC in vivo involving human skin grafts and adoptive transfer of human 
PBMC in immunodeficient mice (179). To determine which T cell subsets contribute to 
graft EC injury, I adoptively transferred purified T cell subpopulations and compared the 
results to those observed following transfer of PBMC. CD4+ plus CD8+ T cells were 
isolated from whole PBMC and then further fractionated into memory and naive subsets 
based on negative selection of CD45 isoform expression (Figure 3.2A). Memory 
(CD45RO+) or nai've (CD45RA+) T cells were then injected i.p. into SCID/beige mice 
engrafted with human skin. One week later circulating CD3+ T cells were present in 
similar numbers following adoptive transfer o f either CD45RO+ or CD45RA+ T cell 
subsets as shown by FACS analysis of mouse blood (Figure 3.2B). Interestingly, mice 
reconstituted with CD45RA+ T cells developed some circulating CD45RO+ T cells 
(Figure 3.2B) in addition to circulating CD45RA+ T cells, consistent with observations 
that naive T cells acquire some memory markers during homeostatic proliferation (44). 
In contrast, mice receiving purified CD45RO+ cells displayed exclusively CD45RO+ 
cells in their circulation. Similar to effects following adoptive transfer of whole PBMC, 
neither human T cell subset appeared to infiltrate or injure any mouse tissue (data not 
shown).
Human skin grafts were harvested from the mice at 15 days after adoptive transfer 
o f T cells and analyzed using histology, immunohistochemistry and quantitative real-time 
PCR (qRT-PCR). Hematoxylin and eosin (H&E) (Figure 3.3A) and anti-CD3 (Figure 
3.3B) staining showed a significantly different pattern of infiltration and tissue
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Figure 3.2. Injection o f  CD45RO+ (memory) T cells or CD45RA+ (naive) T cells results in 
circulating human T cells in SCID-beige mice. CD45RA+ T cells (naive), CD45RO+ T cells 
(memory) (1.5x 108 cells) or whole PBMC (3* 108) were injected i.p. into SCID mice that had 
been grafted with skin allogeneic to the mononuclear cells. After 7 days, peripheral blood lym­
phocytes where then stained with anti-human CD3-FITC Ab and either anti-human CD45RA- 
PE (top panel) or anti-human CD45RO-PE and analyzed by flow cytometry. As seen in the top 
panel, only mice injected with naive T cells or PBMC have circulating naive cells, whereas 
mice receiving only memory cells do not. The bottom panel shows that mice receiving naive T 
cells, memory T cells or whole PBMC all have circulating memory T cells. The data shown 
represent one of five experiments with similar results (n=15 per group).
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destruction following transfer of naive T cells compared to memory T cells. Transferred 
CD45RA+ T cells produced only limited perivascular infiltrates whereas CD45RO+ T 
cells, like whole PBMC, infiltrated the dermis in a more diffuse pattern. Quantitatively, 
naive T cells showed less total infiltration o f CD3+ T cells compared to memory T cells 
(Figure 3.3C). Naive T cells did not produce histological evidence of EC injury, 
whereas memory T cells, like PBMC, did do so (Figure 3.3C), even when mice given 
naive cells were followed out to five weeks (data not shown). RNA transcripts encoding 
effector molecules (FasL, granzyme B, and perforin) were minimally expressed in the 
CD45RA+ inoculated mice compared to expression following either CD45RO+ T cells or 
unfractionated PBMC inoculation (Figure 3.3D). These data suggest that memory T cells 
largely account for the rejection response observed with whole PBMC since naive T 
cells, though they can enter the circulation and focally infiltrate human skin grafts, do not 
express effector molecules or cause graft injury. Thus, my model provides a means to 
study human memory T cell alloresponses in vivo.
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Figure 3.3. Reconstitution o f mice with memory T cells, but not naive T cells, exhibits a re­
jection response comparable to whole PBMC. Mice were reconstituted with CD45RA+ 
(naive) T cells, CD45RO+ (memory) T cells, or PBMC and then grafts were then harvested at 
21 days for analysis, (a) H&E staining demonstrates that mice reconstituted with memory cells 
exhibit an infiltration pattern (full dermis, ablation o f the dermal papillae architecture) similar 
to whole PBMC, while naive cells exhibit a much more focal, perivascular infiltrate that does 
not damage the dermal architecture (n=18) (b) CD3 staining o f the infiltrated dermis confirms 
that the infiltrate observed in the H&E is human T cells, (c) CD3+ T cell counts showed a de­
creased number o f naive T cells infiltrating the skin graft compared to memory T cells and only 
the mice reconstituted with memory T cells or whole PBMC show significant endothelial dam­
age and vascular thrombosis, (d) qRT-PCR of RNA isolated from grafts at Day 10 indicate that 
memory cells express much higher levels o f FasL, granzyme B and perforin than naive cells, 
though less than whole PBMC (n=9). Data are analyzed using standard curves generated from 
plasmids and normalized to CD3s transcripts.
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3.3 DISCUSSION
First, I show that human microvascular EC, in this instance HDMEC, 
preferentially activate allogeneic CD4+ and CD8+ T memory T cells, defined by 
expression o f CD45RO, but not naive T cells. Second, I demonstrate that following 
adoptive transfer in immunodeficient mice, memory but not naive T cells can attack 
human microvessels in skin grafts allogeneic to the T cells.
Many previous studies examining the role of EC in T cell activation have focused 
on EC derived from large vessels (namely HUVEC) (208, 209, 327). However, in 
allograft rejection and many other inflammatory situations, it is not the macro vasculature, 
but rather the microvasculature, that may be responsible for the recruitment of 
inflammatory cells, initiation of the immune response and eventually the target o f the 
alloresponse. Microvascular EC in rejecting grafts express adhesion molecules important 
for T cell recruitment, namely ICAM-1, VCAM-1 and E-selectin (191, 328) and may 
have prolonged expression compared to HUVEC (323). Furthermore, MHC class II was 
shown to be expressed basally on microvasculature in unstimulated, untransplanted hearts 
and was up-regulated following rejection episodes (329). The microvasculature has also 
been shown to activate CD4+ and CD8+ T cells, however they appear to possess different 
requirements for activating T cells compared to macrovascular EC (208, 215, 330). This 
difference may be due to a difference in costimulator expression. For example, HUVEC 
express the costimulatory molecules LFA-3 and CD40, but lack both B7 molecules,
CD80 and CD86 (122); however, unlike IIUVEC, microvascular EC from cardiac tissue 
express CD80 after CD40 ligation (191). I have not detected CD80 or CD86 on the 
HDMEC used in my experiments. Finally, microvascular EC are the primary target of
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rejection in vascularized organ transplants (179). Due to the important role o f the 
microvasculature in the alloimmune response outline above I focused my study on their 
behavior. I show in my study that HDMEC, like HUVEC, have the capacity to activate 
memory (CD45RO+) T cells, but not naive (CD45RO-) to proliferate and produce 
cytokines.
Memory T cells are thought to play an important role in allograft rejection. In 
particular, memory T cells may have important roles in rejection resistant to 
immunosuppressants because the activation requirements of memory T cells appear to be 
less stringent that those of nai've T cells (318), and may be more difficult to inhibit and to 
tolerize (275, 293). Several previous studies have reported the presence of memory T 
cells (CD45RO+) in heart and kidney allograft biopsies and in the peripheral circulation 
correlated with the incidence and intensity of rejection (267, 331). Heeger et al. also 
showed that pretransplant frequency o f donor-specific memory T cells correlates with 
risk of rejection post-transplantation despite high levels of immunosuppression (271). 
All these studies suggest that memory cells could play a large role in determining the 
survival o f human allografts; however direct experimental evaluation in humans systems 
has not been possible. I establish here using purified human T cell subsets that the 
human PBL-SCID mouse model of skin allograft injury is an example of memory T cell- 
dependent allograft rejection. At three weeks following adoptive transfer of memory T 
cells, the grafts had intense mononuclear infiltrates and significant injury to the
microvasculature, however nai've cells transferred to the same mice demonstrated no 
evidence of injury even when followed out to five weeks after the adoptive transfer.
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In sum, I show that in vitro that HDMEC activate resting memory T cells and 
demonstrate that memory T cells are the major effector population of human allograft 
rejection following adoptive transfer into immunodeficient mice bearing human skin 
grafts. This chapter presents data introducing a small animal model to study human 
memory T cell reactions to allografts.
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CHAPTER IV -  TARGETING CD28 IN EC-MEDIATED T CELL 
ACTIVATION
4.1 INTRODUCTION
Optimal T cell activation requires the engagement of two signals, the T cell 
receptor (TCR) and a costimulatory molecule. The CD28/CTLA-4/B7 is perhaps the 
best-characterized costimulatory pathway. CD28 is a receptor expressed on resting 
CD4+ T cells, some CD8+ T cells, NK cells, neutrophils and eosinophils and binds to 
either B7.1 (CD80) or B7.2 (CD86), ligands which are expressed on professional antigen 
presenting cells (APC) (80). Binding of either of these ligands to CD28 increases IL-2 
production, provides a survival signal for T cells, and regulates entry of T cells into the 
cell cycle (332, 333). Both B7.1 and B7.2 also bind to CTLA-4, an alternate receptor, 
with higher affinity than they do to CD28. CTLA-4 is primarily expressed by activated 
CD4+ and CD8+ T cells and, in contrast to CD28, CTLA-4 is thought to provide negative 
costimulation (80, 334), functioning to shut off T cell responses and perhaps contributing 
to the induction o f tolerance. Soluble CTLA-4Ig can effectively inhibit T cell activation 
by competing with CD28 for B7.1 and B7.2 molecules (335). However, since CTLA-41g 
also prevents signaling via CTLA-4, it may prevent the acquisition of tolerance (336). 
Therefore, a reagent that selectively targets CD28 could be a more desirable 
immunotherapeutic than CTLA-4Ig because it would allow inhibitory CTLA-4 signals to 
be received in the absence o f positive CD28 signals.
Human EC are not known to express B7 molecules and several studies 
demonstrated that their capacity to activate CD4+ and CD8+ T cells depends on the CD2- 
LFA-3 pathway (98, 209, 239). However, B7 molecule expression can be triggered on 
CD4+ T cells co-cultured with EC and these molecules may provide a costimulatory
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signals to other T cells in trans (190). It is not known what role if  any these trans B7 
signals play in vivo nor for CD8+ T cells. In mice, EC express CD80, but not CD86 
which is critical for the murine EC capacity to activate CD8+ T cells, but insufficient for 
murine EC to activate CD4+ T cells (216, 219).
One approach to selectively target CD28 is to use an antibody to this receptor. 
Using monovalent recombinant antibodies, Vanhove et al. showed that selectively 
targeting CD28 could in fact block a human MLR reaction (337). A rat model of 
transplantation using an antibody that induces CD28 internalization demonstrated that 
functional blockade of the CD28 pathway could induce tolerance (338). While effective 
in vitro, monovalent antibodies are unlikely to display sufficient avidity or half-life to be 
useful in vivo. Most intact antibodies to human CD28 have been agonistic, replacing and 
often exceeding rather than inhibiting CD80 and CD86 signals. Moreover, the properties 
o f anti-CD28 mAb have been unpredictable, showing different effects in vitro than in 
vivo. In this chapter, I describe the properties o f a humanized IgG2 antibody, designated 
FK734 (Astellas Pharma Inc.), that incorporates the variable regions derived from mouse 
antibody against human CD28 (clone TN228) and the constant regions from human IgG2 
antibody with mutations in the Fc portion of the heavy chain of human IgG2 to prevent 
binding of the antibody to FcyR. These modifications are designed to make FK734 a 
candidate for use as an immunosuppressant in humans. I find that FK734 is a partial 
agonist in vitro. More importantly, this reagent reduces the extent of T cell-mediated 
damage to a skin graft in a chimeric human-mouse model of human allograft rejection in 
vivo.
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4.2 RESULTS
FK734 stimulates T  cell cytokine production and proliferation in co-culture with 
allogeneic EC or Mo.
I began my analysis of FK734 (anti-CD28 antibody) by examining its effect on 
CD4+ and CD8+ T cells separately co-cultured with allogeneic EC (HUVEC), APCs that 
do not express B7 and FcRy molecules. HUVEC were treated with IFN-y for 3 days to 
induce HLA-DR expression prior to co-culture with allogeneic, CFSE-labeled CD4+ T 
cells. HUVEC for co-culture with CD8+ T cells were untreated. Media was collected at 
24 hours for measurement of cytokines and T cells were collected after 7 days for 
analysis of proliferation. Supernatants collected at 24 hours demonstrated that addition 
of FK734 to the T-EC co-culture increased production of both IFN-y and IL-2 in 
comparison to a control IgGl for both CD4+ (Figure 4.1A) and CD8+ (Figure 4.1C) T 
cells. In contrast, T cells co-cultured with EC and an anti-LFA-3 mAb (TS2.9), a reagent 
that blocks costimulation of human T cells via CD2, showed significantly less IFN-y and 
IL-2 production (Figure 4.1 A and C). I additionally examined the effects of FK734 in 
CD4+ and CD8+ T cell co-cultures with allogeneic Mo, a cell type that basically 
expresses low levels of HLA-DR, CD86 and FcRy (339, 340) . T cells co-cultured with 
Mo show the same pattern of upregulation of IFN-y and IL-2 secretion by FK734 and 
inhibition by TS2.9 compared to IgGl (Figure 4 .IB and D). Similar results were 
obtained at 48 hours for both CD4+ and CD8+ T cells (data not shown).
Proliferation o f the T cells in T-EC or T-Mo co-cultures as assessed by CFSE 
dilution mirrored 24-hour cytokine production. Positively isolated CD4+ and CD8+ T 
cells were collected from co-cultures at day 7 and stained with anti-CD4 or anti-CD8
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Figure 4.1. T-EC and T-Mo co-culture shows increased IFN-y and IL-2 production in the 
presence o f  FK734. Positively isolated CD4+ T cells (A, B) or CD8+ T cells (C, D) were cul­
tured in the presence of endothelial cells that were pre-treated with IFN-y (A, C) or adherent 
Mo (B, D) and incubated with either IgGl (2 ug/mL), anti-CD28 (FK734) (2 ug/mL), or anti- 
LFA-3 (TS2.9) (2 ug/mL). Supernatants were collected at 24 hours and assessed for IFN-y and 
IL-2 by ELISA. T cells, EC and Mo alone all produced less than 5 pg/mL of IFN-y and IL-2. 
Data represents one of five similar experiments.
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antibodies and analyzed by FACS. Addition of FK734 significantly increased the 
number of proliferated cells in both the T-EC and T-Mo co-cultures compared to an IgG 
control (Figure 4.2A and B). TS2.9 was mildly inhibitory in the same assays. Thus, in 
allogeneic co-cultures, FK734 has agonist activity.
T cells co-cultured in the presence o f  B7.2-transduced endothelial cells show inhibition 
o f  IL-2 but not IFN-y production and reduced proliferation with FK734.
Since addition of FK734 to standard T-EC or T-Mo co-cultures demonstrated 
agonistic effects, I sought to understand if  the antibody could be inhibitory in a condition 
where strong signals via CD28 would be present at the time of initial activation. As EC 
do not express B7-molecules I transduced endothelial cells with retrovirus encoding B7.2 
(CD86) and then examined the effects of adding FK734. B7.2 transduced EC plus IgGl 
or FK734 were either pre-treated with IFN-y for three days then co-cultured with 
positively isolated CD4+ T cells or directly co-cultured with positively isolated CD8+ T 
cells. When compared to EGFP-transduced EC, both CD4+ and CD8+ T cells co- 
cultured with B7.2-transduced EC produced greater amounts of IFN-y (Figure 4.3A) and 
IL-2 (Figure 4.3B). Addition of FK734 further increased the level of IFN-y production 
(Figure 4.3A) for CD4+ T cells, but inhibited IFN-y secretion by CD8+ T cells (Figure 
4.3D). Both CD4+ and CD8+ T cells showed a marked decrease in IL-2 production 
(Figure 4.3B and E). Consistent with the decrease in IL-2 there was also a significant 
decrease in proliferation of CD4+ and, to a lesser extent, CD8+ T cells co-cultured with 
B7.2 transduced EC and FK734 as assessed by CFSE dilution (Figure 4.3C and F). 
Therefore, it appears that in the absence of B7 signals (as on control EC) or in
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Figure 4.2. T-EC and T-Mo co-cultures show increased proliferation in the presence o f  
FK734. Positively isolated CD4+ T cells (A) or CD8+ T cells (B) stained with CFSE were cul­
tured in the presence of endothelial cells that were pre-treated with IFN-y or adherent Mo and 
incubated with the indicated antibody. Co-cultures were harvested at Day 7, stained with anti- 
CD4 and subjected to FACS analysis. Data from five experiments were pooled and plotted.
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Figure 4.3. T cells co-cultured with B7.2 transduced EC in the presence o f  FK734 demon­
strate decreased IL-2 production and proliferation. Positively isolated CD4+ (A, B, and C) or
CD8+ (D, E, and F) T cells were co-cultured in the presence of EC transduced with retrovirus 
encoding human B7.2 (CD86) and pre-treated with IFN-y and either with or without FK734 (2 
ug/mL). Supernatants were obtained at 24 hours and assessed for IFN-y (A, D) and IL-2 (B, E). 
Co-cultures were then harvested at Day 7, stained with anti-CD4 and subjected to FACS analy­
sis (C, F). Data represents one of four similar experiments.
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the presence of modest B7 signals (as on Mo, Figure 4.3S) FK734 has agonistic effects, 
however in the presence of a strong B7 signal (as on transduced EC), the same reagent 
has some antagonistic actions on CD8+ T cell IFN-y production and both CD4+ and 
CD8+ T cell IL-2 production as well as proliferation.
FK734 stimulates less cytokine production and proliferation in comparison to another 
costimulatory anti-CD28 antibody (28.2).
I next compared FK734 to another anti-CD28 antibody with known costimulatory 
activity (clone 28.2). When either CD4+ or CD8+ T cells were co-cultured with 
allogeneic HUVEC, FK734 stimulated IFN-y production at low doses, but did not 
stimulate further IFN-y production with increasing concentrations. In contrast, 28.2 
induced more IFN-y production at similar concentration and this effect increased with 
higher levels of mAh (Figure 4.4A and D). FK734 stimulated significantly less IL-2 at 
all concentrations tested compared to 28.2 (Figure 4.4B and E). Consistent with the 
stimulation o f less IL-2 production, FK734 also stimulated less proliferation at all 
concentrations when compared to 28.2 (Figure 4.4C and F).
FK734 inhibits the rejection response in the hu-SCID chimera.
Finally, I examined the effect of FK734 on an allogeneic response in vivo. I have 
previously described a model of human T cell responses to allogeneic skin microvascular 
EC in vivo involving human skin grafts and adoptive transfer of human PBMC, 
allogeneic to the skin donor in immunodeficient mice (179). I used qRT-PCR to compare 
the levels of expression of various components of the CD28 system in these
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Figure 4.4. CD80 and CD86 expression on EC, transduced EC, and Mo. EC (top), EC- 
transduced with a retrovirus encoding B7.2 (middle) and Mo (bottom) were stained with anti- 
CD86 (filled histograms, left side of panels) and anti-CD80 (filled histograms, right side of pan­
els) and subjected to FACS analysis. The open histograms are IgGl for the indicated cell types. 
Data shown is one of three similar experiments.
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Figure 4.5. FK734 exhibits less costimulatory activity than another anti-CD28 antibody at 
similar concentrations. Either FK734 or 28.2 were added to co-cultures of CD4+ (A, B nd C) 
or CD8+ (D, E, and F) T cells and IFN-g pre-treated EC in the concentrations indicated. IFN-g 
(A, D) and IL-2 (B, E) production were assessed by ELISA after twenty-four hours of co­
culture. Proliferation was assessed by CFSE dilution at 5 days using FACS analysis. The per­
centage of CFSEloCD4+ cells were plotted for each antibody concentration (C, F). Data repre­
sents one of three similar experiments.
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human skin grafts (Table 1-4) in the absence of PBMC inoculation. Levels of CD3s, 
CD28, CTLA-4 (CD 152) and B7.1 (CD80) were all very low, requiring approximately 30 
cycles of amplification to reach the threshold of detection. B7.2 (CD86) was somewhat 
higher. The addition of PBMC led to a significant increase in all o f these molecules 
except B7.2. These data suggest that CD28 and its principal ligands are present within 
rejecting skin grafts.
Previous experiments using blocking antibodies in this model demonstrated that 
some inhibitory antibodies could be given prior to adoptive transfer without effecting 
circulating T cell levels. However, initial pilot experiments with FK734 showed that 
administration o f this antibody either immediately before or shortly after adoptive 
transfer (within 3 days) inhibited the successful transfer of human PBMC (Figure 4.5A). 
However, if I injected 3 x l0 8 human PBMC i.p. into mice and began administering 100 
ug (2.5 mg/kg) o f FK734, anti-LFA-3 (TS2.9) or IgGl s.c. once every three days starting 
one week after adoptive transfer, then the inhibitory effect on adoptive transfer was 
minimized (Figure 4.5B).
After determining that delayed administration o f FK734 does not significantly 
affect adoptive transfer of human PBMC, I examined the effect of the antibody on graft 
rejection mediated by the transferred PBMC. Split thickness human skin was grafted 
onto SCID-beige mice and allowed to heal for 4-6 weeks. Human PBMC were then 
transferred into mice at day 0, one week later on day 7 100 ug of IgG l, FK734 or TS2.9 
were given to the mice. Another dose was given at day 10 and the grafts were harvested 
at day 14. Grafts were collected for RNA isolation or fixed in formalin, sectioned and 
taken for H&E staining. The resulting slides were scored blindly by a dermatopathlogist
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GAPDH 19.5±0.4 18.6±0.5 1.9 0.032
CD3e 31.4±1.0 28.4±0.4 8.1 0.002
CD28 29.5±0.7 27.6±1.3 3.8 0.45
CD80 31.3±1.2 28.8±0.7 5.4 0.013
CD86 27.2±1.1 27.6±0.7 0.7 0.58
CD 152 31.1±1.0 28.8±1.1 4.9 0.013
Table 1-4. Expression o f  the CD28 fam ily o f  molecules in skin grafts.
RNA was isolated from skin grafts on mice that had either not received any PBMC (- 
PBMC) or received 3X108 PBMC (+PBMC) and were assessed for expression of the 
indicated mRNA by real time qRT-PCR as described in the methods. Values listed are 
threshold cycles and are the average from twelve mice (n=12).
















Figure 4.6. Delayed administration o f  FK734 in mice does not affect adoptive transfer o f  hu­
man T cells. Mice were given 250 ug of either IgG l, FK734 or TS2.9 at either the same time 
as the adoptive transfer (A) or one week following adoptive transfer (B). On Day 14, adoptive 
transfer was assessed by staining blood obtained via retroorbital bleed for human CD3 and 
mouse CD45. The percentage of CD3+ and mCD45- cells was assessed by FACS and plotted. 
Data represents twelve mice (n=12) per group.
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(JMM). Administration of FK734 reduced endothelial injury and thrombosis when 
compared to the IgG control at one week (Figure 4.6A) and only endothelial injury at two 
weeks (Figure 4.6B). The reduction in injury was comparable to that observed with 
TS2.9, whose protective effects have been described previously (109).
Further analysis of the grafts using immunohistochemistry to quantitate the 
number of CD3+ cells and CD31+ vessels showed an increased presence o f CD31 + 
vessels at one week (p<10'5, Figure 4.6D) and two weeks (p<0.002, Figure 4.6D) 
compared to IgGl and decreased infiltration o f CD3+ cells at one week (p<10‘4, Figure 
4.6C) and two weeks (p<0.008, Figure 4.6C) compared IgGl. I have previously shown 
that rejection in this model is largely dependent on memory T cells in that when PMBC 
are fractionated into memory (CD45RO+) and naive (CD45RA+) subsets that only 
memory T cells can mediate graft rejection (see chapter III). Thus, the data presented 
here suggests that CD28 may play a role in this largely memory T cell-dependent 
response.
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Figure 4.7. Pathology scoring, vessel counts and cell counts o f  day 7 and 14 grafts demon­
strates decreased endothelial injury and significant reduction in infiltrating T cells with ad­
ministration o f  FK734. Grafts from either day 7 (A) or day 14 (B) were scored blindly by a 
dermatopathologist on three criteria, infiltration, endothelial injury, and thrombosis using a 
semiquantitative scoring scale with 4 indicating 100% graft involvement and 0 indicating 0% of 
graft involvement. Data shown is pooled data from four separate experiments. Grafts har­
vested at either day 7 or day 14 were sectioned and stained for CD3 (C) and CD31 (D). Human 
CD31 positive vessels and human CD3 positive T cells were scored by counting 10 high pow­
e r e d  f i e l d s  per graft.
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4.3 DISCUSSION
The primary goal of the studies in this chapter was to characterize a humanized 
antibody to human CD28 that may have utility as an immunosuppressive in a model of 
memory T cell mediated allograft rejection. This reagent, designated FK734, has both 
agonistic and antagonistic effects in vitro, depending on the strength o f the CD80/CD86 
signals provided by the APCs. Interestingly, the antagonistic effects of FK734 are most 
evident on production of IL-2 and proliferation in CD4+ T cells whereas the antibody 
seems agonistic for IFN-y production even in the presence of strong B7 signals. 
However, under the same conditions, FK734 antagonizes both IFN-y and IL-2 production 
in CD8+ T cells. The basis of these differences is unknown. Since human CD8+ T cells 
in peripheral blood are heterogeneous for expression of CD28, my data suggest that the 
CD28 expressing subpopulation of CD8+ T cells contribute significantly to cytokine 
production in allogeneic responses of this subset. Most importantly, I demonstrate that in 
an in vivo model of human T cell-mediated allograft rejection this antibody can reduce 
infiltration and endothelial damage, hallmarks of graft rejection.
Understanding the role of CD28/B7 interactions in vivo initially came from 
studies performed in the transplant setting. CTLA-4Ig was one of the first reagents 
identified that could selectively target the B7 pathway. Part of the mechanism of this 
reagent depended on the ability of CTLA-4 to bind with much higher affinity to B7 
molecules, effectively blocking CD28 interactions (335). In mice, CTLA-4Ig treatment 
was described to prolong graft survival and in some cases could even induce donor 
specific tolerance (341). However, CTLA-4Ig and other reagents designed to block the 
interactions of B7 with CD28 may simultaneously prevent negative or regulatory signals
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from being transmitted via CTLA-4. Signaling through CTLA-4 independent of its 
competition with CD28 has been demonstrated to decrease signaling from the CD3 
complex in a transgenic rodent model (342). Also, it has been shown that CTLA-4 has a 
role in the development o f regulatory T cells in the transplant setting (343). Thus, 
considering the importance of the signals from CTLA-4, targeting CD28 alone may prove 
more effective. While there is extensive murine and non-human primate data studying 
the effects of reagents targeting CD28, human data has been limited to mostly in vitro 
studies (336, 337). My chimeric mouse model provides in vivo data with human T cells 
using a unique human specific reagent. I find that despite retaining some agonist activity, 
a CD28-selective antibody can reduce T cell infiltration and endothelial damage in an 
acutely rejecting organ. My in vitro data suggest this may be due to decreased T cell 
proliferation secondary to the effects of FK734 on IL-2 production in CD4+ and CD8+ T 
cells receiving a strong B7 signal.
One concern is that the partial agonist activity may boost levels o f IFN-y present 
in animals treated with FK734. Previous data from my lab has shown that microvascular 
endothelial cells in human skin grafts retain both MHC class I and II expression in situ in 
the absence of exogenously added PBMC (179), perhaps due to low levels of IFN-y 
produced by the small number of T cells resident in skin (see Table 1-4 for basal CD3s). 
Increased IFN-y production provided by PBMC could further enhance expression on 
endothelial cells and induce de novo expression on other cell types. Such an effect could 
theoretically amplify the allogeneic T cell response to the skin graft. Despite this 
concern, the data show that the overall effect of FK734 in vivo is inhibitory and
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equivalent to that of the anti-LFA-3 antibody, TS2.9, which inhibits IFN-y production in 
vitro.
An anti-CD28 mAb may function through several different mechanisms. First, 
the antibody might block interaction between CD28 and its natural ligands, B7.1 and 2, 
either by steric hindrance or by down modulating CD28 expression. Second, the 
antibody could act as an agonist and stimulate CD28. Third, especially in vivo, the 
antibody may deplete CD28+ cells. The vast majority of intact antibodies reactive with 
human CD28 described to date have been agonistic with the extent of signaling 
downstream of CD28 related to the degree of crosslinking of the receptor (337). 
Therefore, it is not surprising that a modified monovalent antibody that selectively targets 
human CD28 and does not crosslink was shown to inhibit T cell activation in a mixed 
lymphocyte reaction (337). Further, murine models have shown that CD28 Fab 
fragments, which inhibit CD28 signals, ameliorate EAE and uvoretinitis (344, 345). In 
fact, selective blockade of CD28 in the rat was shown to have greater immunosuppressive 
effects than CTLA-4Ig in part through the generation of non-T regulatory cells and the 
induction of indolemine-2,3-dioxygenase (IDO) and iNOS (338). In addition to blockade 
of CD28, there have been reports that suggest the agonistic effects of a CD28 antibody 
may also be paradoxically immunosuppressive through depletion of activated T cells 
(334) or, in the case of superagonists, selective activation of regulatory T cells (346). My 
mouse model cannot support T cell depletion via ADCC, presumably because of defects 
in NK cell-mediated killing due to the beige mutation. FK734 also contains structural 
modifications to prevent FcR binding. I cannot rule out inhibition of tissue injury by 
induction of regulatory T cells and my data indicates the presence of mRNA for CTLA-4
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in rejecting grafts. This possibility warrants further investigation although I do not yet 
know if regulatory T cells are generated or function in my model.
In chapter III, I show that the mouse model of skin graft rejection I utilized in this 
study is mediated principally by memory T cells. Memory T cells have special properties 
compared to nai've T cells including lower activation threshold, faster acquisition of 
effector function, enhanced proliferation potential and increased survival (16). Many of 
the properties o f memory cells reflect changes in the TCR mediated activation of memory 
T cells part of which includes changes in the costimulation requirements (318). The 
CD28/B7 pathway has been studied in the generation and function of memory T cells and 
mouse models have indicated that CD28 signals are not required to mount a CD8+ T cell 
response, but may be important in the CD4+ T cell response (347). My data suggest that 
CD28 signals do play a role in the ability o f human memory T cells to mount an immune 
response in a skin graft rejection model. This finding is interesting in that microvascular 
human EC, the primary target of this alloresponse, do not express detectable levels of 
B7.1 or B7.2. Thus the cellular source of the CD28 signals in this model is unknown, 
though my data shows the presence of B7.2 molecules in the graft at baseline and 
induction of B7.1 with the introduction o f PBMC. It is possible that T cells themselves 
provide B7 signals to other T cells (190). Attempts to confirm a role for CD28 by using 
CTLA-4Ig in the same model were confounded by an unexpected enhancement of T cell 
engraftment and skin graft infiltration and injury (SS and JSP, data not shown). This 
effect is under investigation.
FK734 has been engineered to be a candidate for use in humans as an 
immunosuppressant. My in vivo experiments provide evidence that this antibody may
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function as an immunosuppressant despite its partial agonist actions in vitro. Preclinical 
studies in a humanized mouse model may be particularly important given recent clinical 
trials that demonstrated severe, unanticipated toxicity for another CD28 antibody, 
deemed a “superagonist” that was recently tested in a phase I trial in the UK (348). In 
that trial, all six patients given an experimental anti-CD28 antibody TGN1412 became 
extremely ill even though the antibody had been tested and deemed safe in non-human 
primates (349). It would be interesting to examine if TGN1412 induces cytokine release 
or exacerbates tissue injury in my model of human allograft rejection.
In summary, I describe a humanized antibody that targets CD28 and has both 
agonist and blocking capability. Furthermore, I demonstrate that this reagent has the 
ability to reduce endothelial cell injury in a model of human memory T cell mediated 
graft rejection. This both suggests the potential o f such a blocking reagent in human 
disease and demonstrates a role for CD28 in human memory T cell responses.
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CHAPTER V -  MEMORY T CELL SPECIFIC COSTIMULATORS 
IN EC-MEDIATED T CELL ACTIVATION
5.1 INTRODUCTION
I have shown in the previous chapter that human dermal EC can preferentially 
activate memory T cells and that memory T cells, but not naive can mediate allograft 
rejection in a chimeric human-SCID mouse model o f allograft rejection. The capacity for 
EC to activate memory, but not naive T cells, may arise from differences in the co­
stimulatory signals provided by EC to T cells. This possibility is explored further in this 
chapter.
The T cell response to antigen depends both on TCR signals (provided by 
peptide-MHC molecule complexes) and antigen-independent costimulatory molecules. 
The best described T cell receptors for costimulation are CD28 (which binds B7-1 and -2, 
also known as CD80 and CD86, respectively and is discussed in the previous chapter) 
and CD2. CD2 binds CD48 in rodents, but is preferentially activated in humans by 
LFA-3 (CD58), a molecule missing from the rodent genome (350). Human EC express 
LFA-3 (but generally not B7-1 or -2) and the LFA-3-CD2 pathway seems to be 
particularly important in human allogeneic responses to this cell type. However, 
antibody blocking experiments have suggested that LFA-3 does not account for all o f the 
costimulation that human EC provide to memory T cells (208, 209). Several newly 
discovered receptors for costimulators in both the B7 family (such as ICOS) and the TNF
family (such as 4 - IBB and 0 X 4 0 ) arc important for the generation o f  cffcctor/mcmory T
cells (140, 160, 351, 352) and ligands for these molecules can be expressed at high levels 
on cytokine-activated human umbilical vein EC (HUVEC) (86, 152). It is not know if
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any of these molecules also contribute to the reactivation of resting memory T cells by 
human microvascular EC.
The above observations suggest that circulating human alloreactive memory T 
cells may effectively recognize graft EC in vivo and may do so in a manner dependent 
upon costimulators other than LFA-3, CD80 or CD86. I demonstrate here that ICOS 
ligand (ICOSL), 0X 40 ligand (OX40L), and 4 -IBB ligand (4-1BBL) are inducible on 
cultured human dermal microvascular EC (HDMEC) and that all three molecules 
contribute to EC-dependent memory T cell activation in vitro and graft rejection in vivo.
89
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5.2 RESULTS
HDMEC inducibly express ICOSL, 4-1BBL, and OX40L
LFA-3 is an important costimulator expressed by HUVEC, but blocking the LFA- 
3 interaction with its ligand, CD2, does not fully inhibit proliferation or cytokine 
production by allogeneic T cells (98). To characterize additional molecules involved in 
costimulation, I initially examined FIDMEC with or without treatment with pro- 
inflammatory cytokines (at doses and times shown to be optimal for other HDMEC 
responses), for the expression o f three molecules proposed to act preferentially on 
activated T cells, namely 4-1BBL, ICOSL, and OX40L (CD134L). Specifically HDMEC 
were mock- treated or treated with either TNF (10 ng/mL) or IFN-y (50 ng/mL) for 24, 
48, or 72 hours and collected for quantitative real-time (qRT)-PCR and FACS analysis. 
Mock-treated HDMEC expressed minimal transcript levels and surface expression for all 
three of these memory-selective costimulators. Transcript levels of all three molecules 
were increased many-fold at 24 hours and remain elevated for 4-1BBL and OX40L, but 
not ICOSL, over 72 hours (Figure 5.1 A). There were some differences between surface 
expression and mRNA expression. 4-1BBL surface expression only increased modestly, 
while ICOSL surface expression increased substantially with TNF treatment (Figure 
5.2B). TNF treatment shifted OX40L, which has high basal expression, from a 
heterogeneous population of low and high expressors to a mostly high expressing 
population leading to an overall increase in OX40L expression assessed as corrected 
mean fluorescence intensity (Figure 5.2B). IFN-y did not affect costimulator mRNA or 
protein for any o f the molecules (data not shown).
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Figure 5.1. HDMEC express inducible memory T cell-selective costimulatory molecules.
HDMEC were cultured with cytokines for the indicated times and mRNA levels were calcu­
lated as a percent change from untreated cells, (a) HDMEC cultured with TNF (10 ng/mL) 
showed a 50-fold increase in mRNA for 4-1 BBL at 24 hours that remained elevated for 72 
hours. 6-fold and 8-fold increases in mRNA were observed for ICOSL and OX40L respec­
tively at 24 h that remained elevated for 72h for OX40L, but slowly declined for ICOSL over 
the same time period (filled squares). HDMEC cultured with IFN-g (50 ng/mL) showed no in­
crease in mRNA for either 4-1 BBL, ICOSL or OX40L over 72 hours (empty squares). The 
data shown are pooled from four separate experiments. (b) By FACS analysis, 4-1 BBL, 
ICOSL, and OX40L all show increased surface expression (black line) with 72 hours of TNF 
treatment compared to control, untreated EC (dark grey line). IgG controls which do not 
change with cytokine treatment are shown as filled histograms. The data shown represent one 
o f four experiments with similar results.
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I next evaluated whether these three costimulators molecules are induced when CD4+ T 
cells are co-cultured with IFNy-pretreated allogeneic HDMEC. Using qRT-PCR 
analysis, I found that mRNA for 4-1 BBL, ICOSL and OX40L all increase in HDMEC 
after co-culture with allogeneic T cells. The induction o f 4-1 BBL and OX40L was most 
pronounced at 48h with almost a hundred-fold induction, while ICOSL showed a more 
modest 20-fold induction (Figure 5.2A). Surface expression was then assessed by FACS. 
4-1 BBL increased modestly at day 1 and steadily increased through day 7. ICOSL 
showed immediate increase by day 1 and also continued to increase throughout the co­
culture. OX40L, in contrast, increased at day 1, but then returned to baseline by day 3 
(Figure 5.2B). T cells recovered from the same co-cultures at day 1, 3, 5 and 7 express 
increasing levels of the corresponding receptors (4-IBB, ICOS, and OX-40) to these EC 
ligands on cells that had proliferated, although 0X 40 expression actually declined by day 
7. Surprisingly, these molecules were also increased in expression on some T cells that 
had not proliferated, as assessed by dilution of CFSE fluorescence (Figure 5.2C). I do 
not know if this is a bystander response to cytokines or a response to suboptimal TCR 
stimulation.
Blocking 4-1BBL, ICOSL or OX40L in T cell-EC co-cultures decreases T cell activation 
The parallel induction of the T cell receptors and their EC costimulators suggest 
that these interactions could contribute to memory T cell activation by allogeneic 
HDMEC. I therefore examined the effect of blocking these pathways using antibodies 
and/or fusion proteins in T cell-EC co-cultures. In my experiments, HDMEC were 
treated with IFN-y for 3 days (to induce HLA-DR) for CD4+ T cell stimulation or mock
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Figure 5.2. HDMEC upregulate memory costimulatory molecules in co-culture with T cells 
and stimulate T cells to express the corresponding ligands. HDMEC were co-cultured with 
allogeneic T cells and cells were harvested at 3, 6, 12, 24, and 48 hours for RNA and at Day 7 
for FACS analysis, (a) HDMEC upregulate for mRNA 4-1BBL (filled circle), ICOSL (grey 
square), and OX40L (filled diamond) over the course o f 48 hours, (b) 4-1 BBL, ICOSL and 
OX40L protein expression on HDMEC after 1, 3, 5, and 7 days of co-culture with allogeneic T 
cells (cMFI = corrected mean fluorescent intensities, i.e. cMFI = Ab MFI - IgG control), (c) 
Both proliferating T cells (circled population) and non-proliferating T cells identified by CFSE 
dye dilution, show increasing expression of 4 -IBB, ICOS, and OX-40 at day 1, 3, 5, and 7 of 
co-culturc (numbers represent percentage o f  total T cell population). The data shown represent 
one experiment of four with similar results.
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treated for CD8+ T cell stimulation and then co-cultured with allogeneic T cell subsets. 
Pilot titrations were done in T cell-EC co-cultures to determine maximally inhibiting 
doses of each antibody and fusion protein typically between 4-10 pg/mL (data not 
shown). Cytokines were assessed by ELISA in the supernatants collected from the co­
cultures at 24 hours. By ELISA, I found that blocking either ICOSL or OX40L with 
specific antibodies led to a substantial decrease in IFN-y production by CD4+ T cells, 
while blockade of 4-1 BBL with a fusion protein had little effect (Figure 5.3A). IL-2 
production by CD4+ T cells showed similar decreases (Figure 5.3A). In contrast, 
blockade of any of the three costimulators in CD8+ T cell-EC co-cultures led to at least a 
70% decrease in IFN-y production (Figure 5.3A) when compared to control antibody. 
Overall, CD8+ T cells produce substantially less IL-2 and exhibited a lesser decrease in 
IL-2 production than CD4+ T cells with blockade of any of the three costimulators 
(Figure 5.3A). T cell proliferation was also reduced by blocking each of these
costimulators. For CD4+ T cells, blocking 4-1 BBL or OX40L decreased proliferation by 
almost 35% and blocking ICOSL led to a decrease of almost 45% at day 5 (Figure 5.4A). 
CD8+ T cells also demonstrated decreased proliferation, with 4-1 BBL blockade reducing 
proliferation by 40% and ICOSL or OX40L blockade causing lesser, but significant 
reductions of 26% and 20% (Figure 5.4B). My results suggest that these costimulators 
can contribute to resting memory T cell activation by allogeneic HDMEC. In several 
experiments, combined blockade did not appear more effective than blockade of 
individual costimulators (data not shown). The effects of blocking these pathways were 
comparable in magnitude to those attained with blockade of LFA-3 (Figure 5.3 and data 
not shown). Overall, my in vitro experiments demonstrate that allogeneic HDMEC, like
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Figure 5.3. CD4+ and CD8+ T cell production o f  IFN-g and IL-2 in allogeneic T-EC co­
cultures is decreased when memory costimulator molecules are blocked. CD4+ (a) or CD8+ 
(b) T cells were co-cultured with allogeneic HDMEC pre-treated with IFN-g for 3 days (to 
upregulate MHC Class II). Cytokine production was then assessed by ELISA on supernatant 
collected at 24 hours, (a) CD4+ T cells exhibit >50% reduction of both IFN-g and IL-2 pro­
duction in the presence of blocking abs to ICOSL or OX40L, but not in the presence of the 
blocking fusion protein 4-lBB-Fc. Combinations of antibodies do not show additive blocking 
effects, (b) CD8+ T cells demonstrate a large decrease in IFN-g production in the presence of 
all three blocking reagents, but only modest a decrease in IL-2 production. The data shown 
represents one of four experiments with similar results.
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Figure 5.4. CD4+ and CD8+ T cells show decreased proliferation in the presence o f  blocking 
reagents to the memory costimulatory molecules. Thymidine was added to the co-cultures 24 
hours prior to the time points indicated and the control is T cells alone, (a) CD4+ T cells were 
co-cultured with allogeneic HDMEC that had been pre-treated with IFN-g for 3 days (p<0.02 
for all points at Day 5). (b) CD8+ T cells were co-cultured with allogeneic HDMEC (p<0.02 
for all points at Day 5). The data shown represent one of five experiments with similar results.
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HUVEC, selectively activate memory T cells and that several newly described 
costimulators, which are inducible on HDMEC, contribute to the alloresponse.
Memory T  cell-selective costimulators contribute to human allograft injury in vivo
To evaluate the function of the memory T cell-EC costimulatory interaction in 
vivo, I again used my model o f human skin allograft rejection in immunodeficient mice. 
I first investigated whether skin grafts in my alloimmune response express these ligands. 
Although basal expression was low, I found a large increase in the mRNA expression of 
4-1 BBL and ICOSL following PBMC transfer; OX40L showed a more modest increase 
(Figure 5.5A). These increases may be explained by the presence of TNF in the 
circulation following adoptive transfer of human PBMC (353). Unfortunately, the 
reagents available for FACS analysis of cultured cells are unable to detect these 
molecules in tissues so I could not directly assess protein expression in the skin grafts.
To investigate the role of memory T cell-selective costimulators in the 
progression o f immune-mediated damage in human skin grafts, i.p. injections of blocking 
antibodies or IgG control were administered three times a week to groups of animals with 
healed human skin grafts starting on the day before i.p. inoculation with PBMC. The 
dosing schedule used was one that gives circulating trough levels of Ig sufficient to match 
in vitro levels. Within each experiment, all skin grafts were obtained from a single donor 
and all PBMC came from a second donor allogeneic to the skin graft donor. Data from 
five independent experiments were pooled for analysis; in each experiment, additional 
control animals bearing skin grafts were injected with blocking antibodies or IgG control 
and were not inoculated with PBMC to be certain that injury was not caused by the
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Figure 5.5. Rejecting skin grafts in the human-SCID chimera upregulate mRNA for the 
memory costimulatory ligands and blocking these pathways decreases rejection pathology.
mRNA was harvested from skin grafts that had been on mice reconstituted for 10 days with 
PBMC. Quantitative PCR on the mRNA harvested from these grafts showed an induction of 
mRNA for 4-1 BBL, ICOSL and OX40L (n=12) (a). Similar grafts were then harvested from 
mice that had been reconstituted for 10 days with PBMC that had also been receiving i.p. injec­
tions of blocking ab (100 ug) every three days, (b) 10 random high-powered fields (HPF) were 
taken of slides cut from the grafts and stained for human CD3e for assessment. Counts of the 
CD3e+ T cells showed similar levels o f T cell infiltration except for LFA-3, which showed a 
significantly decreased number of infiltrating T cells (p<0.001). H&E slides were generated
from these grafts and subsequently evaluated by a dcrmatopathologist blinded to the treatment.
Blocking 4-1BBL, ICOSL or OX40L reduced endothelial injury (p<0.004, 0.05, 0.0003, respec­
tively) and thrombosis (p<0.01, 0.1, 0.002), despite having similar levels of infiltration (c). 
LFA-3, as described previously, showed decreases in both endothelial injury (p< 10"6) and 
thrombosis (p<0.0004) corresponding with its lower level o f infiltration (n=9 per treatment 
group).
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antibodies. Injury to graft EC was evaluated as microvascular lumenal occlusion or 
shedding of EC, initial steps in human vessel loss (179). Blockade of ICOSL, 4-1BBL or 
OX40L all failed to reduce T cell infiltration while blockade of LFA-3 did do so (Figure 
5.5B). ICOSL blockade decreased endothelial injury and thrombosis, but the difference 
in thrombosis did not achieve statistical significance. Blockade of the 4-1BBL or OX40L 
pathway reduced both endothelial injury and thrombosis to a significant degree (Figure 
5.5C). However, the decrease in endothelial damage was not as effective as that 
observed with blockade of LFA-3.
In a final series of experiments, I used qRT-PCR to examine RNA obtained from 
grafts on animals treated with blocking antibodies. Blockade of 4-1 BBL, ICOSL or 
OX40L all significantly decreased FasL and perforin mRNA production in T cells, 
though blockade had little effect on granzyme B expression (Table 1-5). Analysis of 
cytokine mRNA expression within skin grafts was less clear cut. Blockade o f 4-1 BBL 
caused a decrease in IFN-y, IL-2 and IL-10 mRNA expression compared to control grafts, 
but no change in IL-4 mRNA expression (Table 1-5). In contrast, ICOSL blockade 
showed an increase in IFN-y, a decrease in IL-4 mRNA and a modest decrease in IL-2 
and IL-10 mRNA levels. OX40L blockade, when compared to IgG control, showed 
dramatic reductions in IFN-y, IL-2 and IL-4 expression, but a comparable level of IL-10 
mRNA. Overall there is a better correlation of reduction in cytotoxic effector molecule 
than on cytokine expression with protection of grafts from injury, consistent with the 
correlation of effector molecule transcripts with rejection of human allografts (354, 355).
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Percent inhibition of expression
Treatment FasL Granzyme B Perforin IFN-y IL-2 IL-4 IL-10
4-1BBL 85.6±9.8 8.8±8.0 32.3±21.9 42.141.7 59.648.6 (-4.0±5.1) 47.442.4
ICOS-L 98.3±0.7 (-28.3±14.9) 80.5±4.9 (-51.8410.0) 30.4415.0 63.147.7 59.7411.9
OX-40L 81.8±14.5 0.0±8.2 70.8±10.3 59.345.0 92.8±3.5 95.844.2 6.3±14.3
LFA-3 98.7±0.01 82.3±5.9 74.8±8.9
Table 1-5. Effect o f  antibody blockade on expression o f  effector molecules and 
cytokines.
mRNA from human skin grafts harvested from mice that had been reconstituted for 10 
days with PBMC and receiving i.p. injections of blocking mAbs (100 ug) every three 
days was obtained for qRT-PCR. Data was analyzed by comparing threshold cycles to a 
standard curve generated using plasmid DNA and then expressed as a percentage o f IgG 
control.
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5.3 DISCUSSION
In this chapter I present two new observations relevant for human transplantation. 
First, I show that three recently described costimulatory molecules, namely ICOSL, 
OX40L and 4-1 BBL, are inducible on FIDMEC by TNF or by culture with allogeneic T 
cells, and that these ligands contribute to activation of resting memory T cells by 
allogeneic HDMEC. Second, I show that the three costimulators I have determined as 
inducible on HDMEC in culture are also inducible in human skin grafts and contribute to 
human memory T cell-mediated injury during an alloreaction. Protection correlates with 
reduction of effector molecule transcripts within the infiltrated graft.
I began by looking at the expression of several newly described molecules 4- 
1BBL, ICOSL (also known as B7Rpl, B7h, GL-50 or LICOS) and OX40L (gp34) in 
response to cytokines and T cell co-culture. Previous studies have demonstrated that 
activation of T cells by EC involves the interaction of LFA-3, ICOSL and OX40L (86, 
98, 153), however no data exists regarding 4-1BBL on endothelial cells and only ICOSL 
has been studied on microvascular EC (86). In addition to EC, 4-1 BBL, OX40L and 
ICOSL are expressed on most classical antigen presenting cells (APCs) including 
dendritic cells, B cells, activated monocytes (356-358). ICOS is induced following initial 
activation of T cells and ligation of ICOS leads to augmented proliferation (85) and 
secretion of many effector cytokines (including IL-4, IL-10, IFNy) from CD4+ T cells 
(359). Like ICOS, in humans, 0X 40 is expressed by T cells after ligation of the T-cell 
receptor and was initially identified as a marker of T cell activation (360) and appears to 
be important for proliferation and cytokine production by CD4+ T cells when stimulated 
with HUVEC (231) or allogeneic DC (153). 4 -IBB, like ICOS and 0X40, augments
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cytokine production and proliferation, however it does so for both CD4+ and CD8+ T 
cells (160).
In this chapter, I demonstrate that all three of these molecules are inducible on 
HDMEC in response to TNF, but not IFNy. This is consistent with a previous report of 
ICOSL on HDMEC (86); the expression of OX40L and 4-1 BBL has not been previously 
reported on this cell type. Furthermore, previous studies have not examined expression 
in co-cultures of T cells with human endothelial cells. I show that co-culture of HDMEC 
and allogeneic CD4+ T cells induces expression of both the costimulator on T cells and 
their corresponding ligands on HDMEC. The mRNA for the ligands is induced early on 
EC for all three ligands, however their surface expression differs markedly with 4-1 BBL 
peaking and persisting at Day 7, ICOSL peaking and persisting at Day 3 and OX40L 
peaking at Day 1 and then returning to baseline by Day 3 (Figure 5 .IB). This difference 
in expression may explain the reduction on 24 hour cytokine production in CD4+ T cells 
when ICOSL and OX40L are blocked, but the lack o f effect when 4 -IBB is blocked. 
Surface expression of OX40L did not increase to the degree anticipated by the mRNA. 
The reason for this difference is unclear and under current investigation. Blockade of any 
of the three costimulator molecules seems to have moderate effects on both CD8+ T cell 
cytokine production and proliferation. Preliminary data regarding combinations of 
blockade indicate that the effects are less than additive, consistent with overlapping 
activity (data not shown). CD4+ T cells in co-culture with EC showed increasing 
expression of 4 -IBB, ICOS, and 0X 40 in both the proliferated and unproliferated 
population as measured by CFSE dilution. The increased expression on the proliferating 
cells is consistent with earlier data that showed that these molecules are upregulated on T
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cells upon activation (361, 362), however the increased expression on unproliferated cells 
has not been observed previously and may be a response to cytokines produced by the 
activated cells or may represent responses of T cells that are incompletely activated by 
TCR signals.
Using the human-SCID model I examined the role of 4-1 BBL, ICOSL and 
OX40L in human allograft injury. Several recent studies using rodent transplant models 
have described roles for 4 -IBB, 0X40, and ICOS in vivo. Genetic ablation or antibody 
blockade o f the 4-1BB-4-1BBL pathway prolongs graft survival by reducing T cell 
proliferation and cytotoxicity (305, 363, 364). ICOS deficiency or blockade have also 
been shown in rodent models to improve transplant survival and, in conjunction with B7 
blockade, even induce tolerance (303, 365), although not in all cases (366). OX40L 
blockade, also leads to increased graft survival in presensitized mice in combination with 
B7 blockade (307, 366). When any o f these pathways are blocked in my chimeric model 
of human memory I show significantly decreased endothelial damage, vascular 
destruction and effector molecule mRNA at 10 days, though none seems to be as 
effective as blockade of LFA-3. One reason for this is that LFA-3 may have some effects 
on T cell infiltration into the grafts in addition to any o f its potential costimulatory effects 
although the extent of infiltration was reduced by less than 50%. Thus, my model is the 
first to demonstrate a role for 4-1 BBL, ICOSL and OX40L in human allograft rejection 
in vivo. To date, previous data suggested a correlation between these costimulators and 
graft rejection in human transplantation (367, 368) as well as in other human diseases 
(362), but none have explored the effects of targeting these pathways in humans.
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Though 4-1 BBL, ICOSL, and OX40L appear to have similar potential to reduce 
the allograft rejection, the effects on cytokine transcript expression in vivo reveals 
differences among the functions of these costimulators in vivo. Blockade of 4-1 BBL 
decreased mRNA production of IFN-y, IL-2, as well as IL-10, but had no effect on IL-4. 
This is consistent with observations that 4-1 BBL activates both CD4+ and CD8+ human 
T cells to produce IL-2 and IFN-y independently of B7 interactions (160). In comparison 
to 4-1 BBL, blockade o f ICOSL increased IFN-y and only minimally reduced IL-2 
production, but showed a much larger decrease in IL-10 and IL-4 production. My in vivo 
data correlates with in vitro studies that have indicated a limited role for ICOS in IFN-y 
regulation, while playing a large part in the regulation o f IL-10 (369) and IL-4 (370, 371). 
OX40L blockade had no effect on the level of IL-10 mRNA, while reducing all the other 
cytokines, suggesting a distinct mechanism o f action different from either 4-1 BBL or 
ICOSL blockade and may be related to the role that the 0X40 interaction plays in the 
control o f regulatory T cells (Treg) (372, 373)
In conclusion, I have shown that memory T cell-mediated activation by HDMEC 
depends in part on the costimulatory molecules 4-1 BBL, ICOSL and OX40L. Further 
that memory T cell-selective costimulation plays a significant role in this model of 
memory T cell-dependent allograft rejection. My studies extend the understanding of the 
mechanism by which human memory T cells may be activated by the endothelium and 
identify targets for reducing the memory T cell participation in clinical allograft rejection.
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CHAPTER VI -  THE IN  VITRO AND IN  VIVO RESPONSE OF 
MEMORY T CELL SUBSETS TO THE ENDOTHELIUM
6.1 INTRODUCTION
A cardinal feature of the adaptive immune response is memory, i.e. a second 
immune response to a given Ag that has been encountered previously is faster and more 
vigorous compared to the initial (primary) immune response. In cell-mediated immune 
responses, memory arises from changes in the populations of T lymphocytes that respond 
to the specific Ag. When compared to naive response, a memory response is 
characterized by a higher frequency of Ag-specific T cells and by a series o f changes in 
the individual T cells that respond to that Ag (16). Such changes include an altered 
requirement for costimulators and a change in receptors involved in homing. Memory T 
cells also have a special relationship to vascular endothelial cells (EC) in that resting 
memory T cells can be activated by alloantigens presented by EC, but not by other 
stromal or parenchymal cells in vitro (206, 213).
It has recently been discovered that memory T cells exist in at least two subsets 
based on their homing characteristics and effector functions (46, 51, 54). Central 
memory T cells ( T c m )  express chemokine receptors (e.g. CCR7) that bind lymph node­
derived chemokines like SLC and adhesion molecules (e.g. CD62L) that preferentially 
interact with ligands expressed by high endothelial venules of lymph nodes (46). 
Consequently, Tcm migrate preferentially to the T cell areas of lymphoid organs where 
they conduct surveillance for their specific A g displayed by professional APCs such as 
DC (374). Effector memory T cells ( T e m )  have enhanced effector functions, such as 
secretion of effector cytokines like IFN-y, and a corresponding preference for migration 
to inflamed peripheral tissues (54). This migration pattern is explained by observations
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that T e m  express chemokine receptors (e.g. CXCR3) that respond to inflammatory 
chemokines instead o f CCR7 and express high levels of adhesion molecules (e.g. LFA-1 
or VLA-4) (325) whose ligands (ICAM-1 and VCAM-1, respectively) are preferentially 
expressed by cytokine-activated peripheral vascular EC (200). These homing properties 
are shared with activated effector T cells and may allow circulating effector memory cells 
to be directly recruited to sites o f peripheral inflammatory reactions without first 
requiring Ag recognition and activation in secondary lymphoid organs.
As discussed previously, the T cell response to antigen depends both on TCR 
signals (provided by peptide-MHC molecule complexes) and antigen-independent 
costimulatory molecules. The majority of costimulatory molecules fall into two 
structural families, those that are part o f the Ig superfamily and those that are part o f the 
tumor necrosis factor (TNF) superfamily. The best described T cell receptors for 
costimulation are those from the Ig superfamily, particularly CD28 (which binds B7-1 
and -2, also known as CD80 and CD86, respectively) and CD2 (which binds CD58 in 
humans and CD48 in rodents) (350). Fluman EC express LFA-3 (but generally not B7-1 
or -2) and the LFA-3-CD2 pathway seems to be particularly important in human 
allogeneic responses to this cell type. However, antibody blocking experiments have 
suggested that LFA-3 does not account for all of the costimulation that human EC 
provide to memory T cells (208, 209). Several newly discovered receptors for 
costimulators in both the B7 family (such as ICOS) and the TNF receptor family (such as 
CD27, 4 IBB and 0X40) are important for the generation of effector/memory T cells 
(140, 160, 352, 375). Ligands for these molecules are expressed on cytokine-activated 
human EC cultured from umbilical vein (86, 152) and dermal microvessels (See chapter
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V). Results from Chapter V demonstrate that ICOS, 4 IBB and 0X 40 can contribute to 
EC mediated activation of memory T cells, but the specific costimulatory requirements of 
the different memory T cell subsets has not been fully explored.
In addition to addressing whether naive or memory T cells can mediate allograft 
rejection, the subset o f memory T cells responsible for this phenomenon is not clear. 
Work by Adams et al has shown that CD8+ central memory T cells are principally 
responsible for memory cell-mediated rejection (275) while others have described a role 
for CD4+ T effector cells (376). Little is known about differences between alloreactive 
human T c m  and T e m -
In this chapter I demonstrate that both Tcm and Tem subsets from human 
peripheral blood respond can proliferate in response to allogeneic HUVEC in vitro, but 
that these two subsets respond differently to EC vs. professional APC. Further, I also 
demonstrate in the human-SCID chimeric model o f allograft rejection that adoptively 
transferred T Em  are capable o f mediating rejection whereas human T c m  cannot. These 
observations may be important for the design of new therapies to address the problem of 
immunological memory in transplant rejection.
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6.2 RESULTS
T c m  proliferate more and produce greater amounts o f  IL-2 in response to EC compared 
to T em , while T e m  proliferate less and produce more IFN-y.
Memory T cells in humans have been defined by expression of CD45RO (377). 
These memory T cells can be further divided into separate subsets based on CD62L and 
CCR7 expression (46). I took positively isolated CD4+ T cells from human peripheral 
blood and sorted then for the CD45RO+CCR7+CD62L+ population (“central” memory T 
cells, T c m )  and the CD45RO+CCR7-CD62L- (“effector” memory T cells, T e m )  (Figure 
6.1). T cell subsets were sorted with >95% purity. Previous work from Chapter III 
demonstrated that CD4+ memory T cells but not naive T cells respond to class II MHC- 
expressing HDMEC in vitro. To assess the responses of T c m  v s  T Em , I used the FACS- 
sorted memory CD4+ T cells subsets described above and co-cultured them with EC pre­
treated with IFN-y for 72 h to induce class II MHC molecules, assaying the supernatants 
for IFN-y and IL-2 after 24 h. I found that T e m  cultured with allogeneic EC produce 
significantly more of IFN-y but less IL-2 than do Tcm (Figure 6.2A and B). The 
increased production of IL-2 by Tcm correlates with increased proliferation of Tcm in 
response to allogeneic EC compared to Tem assessed by 3H-thymidine incorporation at 
days 5, 6, and 7 (Figure 6.2C). In contrast I did not observe a difference in IFN-y 
production when these same subsets are co-cultured with allogeneic Mo. However, both 
IL-2 production and T cell proliferation are greater for T c m  compared to T e m  in co­
cultures with allogeneic Mo (Figure 6.2A, B, and D). In other words, EC appear to 
provide a signal that selectively augments IFN-y production by TEM or, conversely, lack a 
signal needed for optimal IFN-y production by Tcm-
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CD45RO CCR7
CD45RO CCR7
Figure 6.1. FACSort o f  human T cells demonstrates good purity o f  subsets. CD4+ T cells 
were isolated using magnetic beads prior to being stained with antibodies to CD45RO, CD62L 
and CCR7. Cells were then sorted into Tcm and T em by collecting only the gated regions.
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Figure 6.2. Effector memory T cells exhibit 
greater IFN-g production and less IL-2 pro­
duction than central memory T cells in re­
sponse to EC, but not monocytes. TCM or TEM 
were cultured with either EC or AMo and su­
pernatant was collected at 24 hours. Super­
natants were then assessed for IFN-g (A) or IL- 
2 (B) using ELISA. T cell subsets were also 
assessed for proliferation at day 5, 6, and 7 us­
ing 3H-thymidine incorporation when cultured 
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T c m  express different levels o f  costimulatory and adhesion molecules compared with Tem -
In order to explore the differences that underlie the varying responses o f Tcm and 
T e m , I  examined the expression level of several known costimulatory and adhesion 
molecules on the surface of the two subsets. I found that for the costimulatory molecules 
that Tcm express significantly more CD27 and slightly more CD28, CD 152 (CTLA-4), 
ICOS and 4-1BB compared to T Em  (Figure 6.3A). Expression of CD27 on T Em  was, 
however, heterogeneous with two populations of cells, a small population with an 
intermediate level o f CD27 expression and much larger population of TEm expressing low 
levels of CD27. Unexpectedly, I found slightly higher levels of expression of LFA-1 on 
T Cm  than on TEM (Figure 6.3A). HUVEC lack ligands that may engage CD28, but do 
express both ICOSL and 4-1BBL (189). They also express ICAM-1 and 2, the ligands 
for LFA-1 (200). Expression of CD70, the ligand for CD27, has not been previously 
described. As shown in Figure 3B, EC do not express CD70 or B7 molecules at rest nor 
do they increase CD70 or B7 molecules with IFN-y treatment or co-culture with T cells. 
Adherent Mo, however, express low levels of CD70 and B7 molecules at baseline.
Effects o f  costimulation blockade on Tcm and Tem response.
Due to the differential expression of CD70 on Mo compared to EC and CD27 on 
Tcm compared to TEm, I examined the effect of adding a blocking antibody to this T cell 
receptor in my allogeneic co-culture experiments. Blocking CD27 decreased production 
o f IL-2 by Tcm but not by TEm in co-cultures with EC or Mo (Figure 6.4C and D, p < 
0.05). Surprisingly, blocking CD27 inhibited IFN-y production in co-cultures of
1 1 1










Figure 6.3. Effector memory T cells express 
lower levels o f  CD27, CD152 (CTLA-4), 4- 
1BB and ICOS compared to central memory 
T cells and EC do not express CD70 or B7, 
but Mo express both. CD4+CD45RO+ T cells 
were isolated from PBMCs using magnetic 
beads and subsequently stained with CCR7 and 
CD62L. The TCM CCR7+CD62L+ (gray 
filled) population was gated on and compared 
with the Tem CCR7-CD62L- (black line) popu­
lation (A). HUVEC or negatively isolated Mo 
were either treated with IFN-g for 3 d, co­
cultured with CD4+ T cells or both and as­
sessed for CD70 expression or binding to 
CTLA-4Ig by FACS analysis (B). Data repre­
sents one of three experiments.
EC + CD4+ T
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EC with Tcm or TEm, but has no effect on co-cultures of either subset with Mo (Figure 
6.4A and B).
I also examined the effects of signaling through CD28 since human Mo but not 
EC express B7 (189). I found that if B7 signaling is blocked using CTLA-4Ig that there 
is no effect on IFN-y production in either subset with EC (Figure 6.4A), but that there is a 
significant reduction in both subsets when they are cultured with Mo (Figure 6.4B, p < 
0.01). For IL-2 production I find that CTLA-4Ig inhibits Tcm, but not TEm IL-2 
production in co-cultures with EC (Figure 6.4C, p < 0.04), but inhibits IL-2 production 
from both subsets in co-cultures with Mo (Figure 6.4D, p < 0.005). To further test if B7- 
mediated costimulation accounts for the decreased IFN-y production in TCm cultured with 
EC I generated EC that express B7.2 using retrovirus (Figure 6.5A). When co-cultured 
with these EC, Tcm produce greater amounts of both IFN-y (p < 0.002) and IL-2 (p < 
lxlO"4). Interestingly, TEm do not produce any additional IFN-y, but do produce 
significantly more IL-2 (p < 0.001), similar to the response when TEm are cultured with 
AMo (Figure 6.5B and C). These data suggest that the absence o f B7-ligands on EC may 
contribute to the reduced capacity of EC to activate TCm- The ability of CTLA-4Ig to 
reduce IL-2 synthesis by Tcm cultured with EC is consistent with a previous study in 
which T cells proved to be the source of B7 ligands (190).
Tem alone can mediate graft rejection in a hu-SCID model o f  allograft rejection.
I have recently shown that human skin injury observed in a human mouse chimera 
can be mediated by isolated memory T cells but not naive T cells (189). Knowing that 
both central and effector memory T cells can respond to EC but that
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Figure 6.4. CD27 and CD28 have different roles fo r  EC and Mo in stimulating memory T 
cell subset cytokine production. Tcm and TEM were then co-cultured with EC (A, C) or Mo (B, 
D) and blocking antibody to CD27, CTLA-4Ig or IgG l. ELISAs were performed for IFN- 
gamma (A, B) or IL-2 (C, D). Data represents four experiments with similar results.
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Figure 6.5. Differences in central and  
effector memory T  cell IF N -g  production  
are abolished in the presence o f  CD86 
(B7.2). EC were transduced with a retro­
virus containing the full-length mRNA of  
B7.2 and checked for expression (A). TCm 
and Tem were cultured with either B7.2 or 
EGFP transduced EC and supernatants 
were assessed for IFN-g (B) and IL-2 (C).
EGFP EC B7.2 EC
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only effector memory T cells can produce high amounts o f IFN-y, I wanted to see which 
memory T cell subset was responsible for the rejection response. I adoptively transferred 
either central or effector memory T cells into SCID/beige mice that had been grafted with 
human skin. After three weeks, the grafts were harvested and analyzed. I found in three 
separate experiments that effector memory T cells (Figure 6.6C and D), but not central 
memory T cells (Figure 6.6A and B) could infiltrate and destroy graft microvessels. 
When scored by a blinded dermatopathologist, mice receiving adoptively transferred 
effector memory T cells showed significantly more infiltration and endothelial damage (p 
> 0.0001) compared to mice receiving central memory T cells (Figure 6.6E).
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Figure 6.6. Effector memory T  cells alone can mediate graft rejection. Grafts from mice that 
received either TCm (20x-A , 40x-B ) or TEM (20x-C, 40x-D) for 14 days were harvested and 
stained with H&E. Grafts were then scored blindly by a dermatopathologist (E). The data rep­
resent n=12 mice per group.
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6.3 DISCUSSION
In this chapter, I present two new observations about memory T cell subsets and 
their relationship to EC. First, I demonstrate that human Tcm and Tem subsets, defined by 
the expression o f CCR7 and CD62L, produce different levels of cytokine in response to 
allogeneic endothelial cells. Specifically, TCm produce less IFN-y and more IL-2 
compared to Tem when co-cultured with EC but not with allogeneic peripheral blood Mo. 
Second, I show that both T cell CD27 and CD28 may be involved in the different 
response of memory T cell subsets to allogeneic EC vs. Mo. Third, I demonstrate that 
following adoptive transfer, Tem but not Tcm can mediate graft injury in a hu-SCID 
chimera model of skin allograft rejection.
The current conception of T cell memory proposes that the memory T cell pool 
may be divided into central memory (TCm) and effector memory (TEm) (46). This model 
proposes that Tcm cells which are CCR7+ preferentially migrate into secondary lymphoid 
organs and lack immediate effector functions such as IFN-y production or cytolytic 
activity. However, TEm, which lack expression of CCR7, more rapidly acquire effector 
function and have a migratory pattern that favors extralymphoid sites. Studies in mice 
have demonstrated that a large number of CD4+ memory T cells can be found in 
extralymphoid sites and that there is a functional difference between memory T cells 
residing in the lymphoid tissue compared to those of the extralymphoid tissues (51, 54). 
However, several human and mouse studies have not been able to confirm the 
relationship between immediate effector function and the potential to migrate to 
extralymphoid sites (as defined by the expression of CCR7). In fact, these studies 
suggest that the majority of cytokine producing memory T cells express CCR7 and that
118
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immediate effector function did not correlate with CCR7 or CD62L expression (378- 
380). My data shows that human memory T cell subsets do show such differences but 
only when responding to allogeneic EC. One consideration, however, is the definition of 
T c m  and T e m , some groups use CCR7 alone and others have used CCR7 in combination 
with CD62L. As seen in figure 6.1 there is a significant population that is CCR7- but 
CD62L+; the contributions of this subset are unclear.
It is now become evident that the existence of memory T cells presents a 
significant challenge to long-term graft survival. The presence of alloreactive CD4+ 
memory T cells correlates with increased episodes o f acute rejection and diminished graft 
function (270, 271). However, the role of memory T cells in allograft rejection has not 
been well-studied due to the lack of appropriate in vivo models. Mouse models have 
been described that use donor-specific alloreactive memory T cells (376) or those that 
have been generated from viral infection (275), but these still lack the diversity of the 
human memory T cell pool. My study using human memory T cells fractionated into 
their different subsets shows a role for Tem in allograft rejection, but not Tcm- One key 
difference between my human-mouse chimera and the current mouse models is that, 
though SCID/bg mice possess lymph nodes, human T cells cannot effectively circulate to 
the mouse secondary lymphoid organs thus providing an isolated model of peripheral 
rejection only. I did not find any human T cells in any lymph nodes examines and this 
lack of ability to circulate in the secondary lymphoid organs may explain why, in contrast 
to experiments with mice, T Cm  in my model appear unable to mediate graft rejection. 
This is supported by my in vitro data suggesting that Tem can produce more IFN-y in 
response to the endothelium compared to Tcm which produce significantly more IL-2.
119
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
This difference in vitro is abolished with sufficient B7-signals (i.e. from monocytes or 
transduced EC) which further supports the idea that TCm may need to circulate through 
the secondary lymphoid organs and encounter B7 bearing APC to attain full functional 
capacity.
Recent data have suggested that memory T cells may have different costimulatory 
requirements for activation when compared to their naive counterparts. Early work in 
mice (60) and humans (381) demonstrated that memory T cells can be activated 
independently o f CD28 and more recently it has been appreciated that there may be a role 
for memory specific costimulators in memory T cell activation (361, 362). In accordance 
with other studies that have shown decreased CD27 and CD28 in the effector memory T 
cell population (131, 382), I have also found decreases in CD27 and CD28 in the effector 
memory populations used in my experiments. To explore whether the differential 
expression of these costimulatory molecules on the two different subsets is responsible 
for the difference in their response to EC I used a blocking antibody to CD27 and 
CTLA4-Ig to block the B7-interaction. My results were surprising in that blockade of 
CD27 showed decreased IFN-y production from the effector memory T cell subset as 
well as decreased IL-2 production from the central memory T cell subset. One possible 
explanation is that the majority of the IFN-y may be produced by the sub-population in 
the effector memory T cells that are expressing CD27 at an intermediate level and thus 
blockade of CD27 decreases their IFN-y production. The other possible explanation is 
that blockade of CD27 of this intermediate population may be affecting the production of 
IFN-y production from the CD27- population. The other surprising result from my 
blocking experiments was the effect that CTLA-4Ig had on IL-2 production in the central
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memory T cell population co-cultured with EC. As EC do not express B7 molecules it is 
unclear where the source o f CD28 stimulation for the central memory T cells is 
originating. One source of CD80 and CD86 may be the T cells themselves. Previous 
work has demonstrated that interaction o f CD4+ T cells with EC can induce expression of 
CD 80 and CD 8 6 on the T cells in vitro (190). The increased IL-2 production in central 
memory T cells may depend on this source of B7 stimulation and my experiments with 
B7-transduced endothelial cells supports this hypothesis in that central memory T cells 
seem to be more responsive to B7 signals than their effector memory counterparts.
There has also been evidence showing that the memory T cell subsets are not 
fixed, but rather retain some flexibility in terms of their differentiation and that 
differentiation into the different subsets may be dependent on the microenvironment 
(383, 384). Endothelial cells may play a central role in the determination of this 
microenvironment. My data supports this hypothesis in that interaction between the 
different memory T cell subsets and EC produces different responses. Further 
examination o f memory T cell expression of costimulatory and adhesive molecules 
whose ligands are known to be expressed on surface of EC suggests that these molecules 
may play an integral role in the differential stimulation of T c m  and T e m -
In conclusion, I demonstrate here that when the different memory T cell subsets 
are co-cultured with EC, Tcm favor IL-2 production and Tem produce more IFN-y. The 
difference in IFN-y production is abolished in the presence of AMo or B7-transduced EC, 
but the difference in IL-2 production is retained. I also show that in a chimeric hu-SCID 
model of allograft rejection that Tem alone can mediate rejection whereas Tcm cannot. 
This study introduces the idea that EC may activate different memory T cell subsets
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differently and that this differential in activation may have a functional consequence 
allograft rejection.
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CHAPTER VII -  CONCLUSIONS AND FUTURE DIRECTIONS
This thesis describes several new observations. First, I demonstrate that human 
dermal microvascular endothelial cells (HDMEC) like other human EC preferentially 
activate allogeneic memory T cells. Second, I also show that allograft rejection in my 
chimeric human skin-SCID mouse model is mediated by memory T cells. Third, I 
demonstrate that the CD28-B7 pathway may have a role in memory T cell mediated 
rejection by using a novel reagent that blocks CD28. Fourth, I show that E1DMEC can 
express memory T cell specific costimulatory molecules 4-1BBL, OX40L and ICOSL 
and that these molecules have a role in human memory T cell mediated allograft 
rejection. Finally, I describe the different responses of central memory and effector 
memory T cells to the endothelium and provide evidence that Tem alone can mediate 
allograft rejection.
T cell activation by EC
The question o f whether EC can activate CD4+ and CD8+ T cells in vitro has 
been controversial. The first reason is species differences between humans and other 
animals such as mice. My lab has previously demonstrated that HUVEC activate resting 
allogeneic CD8+ T cells to proliferate, produce IL-2 and acquire cytolytic potential (209, 
215). In the human system, FIUVEC preferentially activate memory CD8+ T cells (214). 
Studies done in the mouse have yielded conflicting results. It was initially reported that 
murine cardiac EC are capable of directly activating naive CD8+ T cells (385), however a 
subsequent study using a model of indirect presentation suggested that IFN-y activated 
lung microvascular EC fail to induce proliferation or activation of naive CD8+ T cells
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(386). Further studies using murine aortic EC have shown that both resting and IFN-y 
activated EC are capable of activating naive CD8+ T cells (219). Since EC in those 
studies derived from different organs, the conflicting findings among the murine studies 
may be due to the fact that EC from different locations have been shown to display 
significant heterogeneity in function which may include their capacity to activate T cells
(387). Differences between the human and mouse capacity to activate naive allogeneic 
CD8+ T cells may be attributable to the different types of costimulatory molecules 
provided by mouse EC, which express B7, and human EC which do not (388). Despite 
these differences, both murine and human data support the idea that EC possess the 
capacity to directly activate allogeneic CD8+ T cells. The results from Chapter 3 agree 
with these findings in that FIDMEC, like the large vessel-derived HUVEC, are capable of 
activating allogeneic memory CD8+ T cells preferentially over naive CD8+ T cells.
This situation for CD4+ T cells is similar to that of the CD8+ T cells. My lab and 
others have previously demonstrated that HUVEC can activate CD4+ T cells (208, 389) 
and that HUVEC also preferentially activate memory CD4+ T cells (223). McDouall et 
al further showed that EC derived from large vessels and microvessels of the heart can 
activate CD4+ T cells (390). Vora et al verified the capacity of HDMEC to present 
specific Ag in experiments using CD4+ T cells clones (233). Other groups have 
questioned the ability of human EC to activate CD4+ T cells (217, 327) and one reason 
may be the insufficient sensitivity of their assays to detect the initial primary activation. 
Marelli-Berg at al demonstrate that culture of EC with CD4+ memory T cells does enable 
them to be subsequently activated by EC in the presence o f B7 costimulation suggesting 
that the T cells in their assays did receive some signal from the EC (327). I confirm in
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this thesis that HDMEC possess the capacity to activate CD4+ T cells and provide 
evidence that HDMEC specifically activate resting memory CD4+ T cells and not naive 
CD4+ T cells (Chapter 3). Similar to the human data, several groups have provided 
convincing evidence that murine EC do not possess the capacity to activate naive CD4+ 
T cells (216, 385), but may possess the capacity to activate CD4+ memory T cells (391). 
In sum, I show that HDMEC can activate both memory CD4+ and CD8+ T cells, but not 
naive T cells of either subset. This observation is consistent with previous data derived 
from large-vessel human EC, but distinct from murine data in that EC from mice can 
activate naive CD8+ T cells.
Memory T cell models in transplant rejection
Much of the progress in my understanding o f memory has come from studies that 
make use of murine models. Most o f the mice used in these studies do not possess 
significant numbers of memory T cells due in part to the relatively pathogen-free 
environments in which mice are housed and the young age of the mice. Thus, in using 
mice to study memory T cells, the two most common approaches are to generate memory 
T cells prior to a given study (priming) or to adoptively transfer memory T cells that have 
been generated in another source.
As discussed in the introduction, one of the major limitations of the murine 
models of memory used to study transplantation is the lack of the diversity and numbers 
o f memory T cells found in mice compared to those in found in large animals. It is this 
significant population of memory T cells that is thought to underlie the failure to translate 
strategies to inhibit rejection from mice to other animals. In this thesis, I provide 
evidence that the rejection response seen in my previously described model of adoptively
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transferring human PBMC in to human skin-SCID mouse chimeras actually (179) 
represents a model of memory T cell mediated destruction (Chapter 3). Thus, my system 
provides a small animal model to test strategies that target human memory T cells. This 
chimera provides a useful bridge between pure murine models and large animal models 
to test hypotheses developed in mice before embarking on the more costly large animal 
models as shown in Chapter 4 where I test a novel reagent against CD28.
Before discussing how the model can be used, there are several technical 
considerations that may be relevant to the understanding of this model. The first 
consideration is the repertoire o f the memory T cells used in this system. Murine models 
of memory because of their requirement for generating memory T cells and the use of T 
cell receptor transgenics have very precise control of the specificity of the memory T 
cells generated. Thus, it is possible to study the rejection in models o f memory with T 
cells that are limited to cross-reactivity from specific infectious agents (275) or are 
specific for minor antigens (392). My model has much less control of the specificity in 
that my HLA mismatches are random and likely involve multiple major MHC 
mismatches between the skin and the adoptively transferred leukocytes. The implication 
of this is that my model may have an alloresponse that is more difficult to inhibit because 
o f the multiple mismatches and that this model may be more vigorous than a typical 
clinical transplant where the MHC alleles between donor and host, particularly in kidney 
and bone marrow transplants (but not liver or hearts), would be HLA matched (393). 
Therefore, any effects seen in my model may be diminished in comparison to a model 
where the specificity is more limited. This may explain why costimulatory blockade in
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my system, while partially ameliorating graft rejection, does not fully recapitulate the 
results seen using murine models of allograft rejection (305, 306, 365).
A second consideration to note is the role that homeostatic proliferation plays in 
my model. Homeostatic proliferation occurs as a result o f low-affinity recognition of 
MHC-peptide ligands and cytokine in a setting where the T cell compartment has been 
depleted, i.e. lymphopenia (24, 48, 280). These dividing cells appear to transiently 
acquire memory markers and have memory-like function during the period during which 
they are undergoing homeostatic proliferation (43, 44, 394, 395). In T cells undergoing 
homeostatic proliferation there is decreased CD62L, increased CD44 and further these 
cells, like bone fide memory cells, show a decreased reliance on CD28 signaling (396). 
The lymphocytes in my model exhibit this type of change and this is most pronounced in 
the CD45RA group that when adoptively transferred appears to transiently acquire 
CD45RO positivity (See Figure 3.2) suggesting that the T cells in my model are 
undergoing homeostatic proliferation in the mouse. However, in contrast to evidence that 
this conversion of a naive to memory phenotype during homeostatic proliferation leads to 
enhanced rejection (281) it appears that in my model this is not the case. The adoptively 
transferred naive T cells despite acquisition of a memory marker do not seem capable of 
mediating a rejection response. This may be because naive T cells require activation in 
secondary lymphoid organs whereas memory T cell do not (61). In my model there are 
no human dendritic cells in addition to the fact that human T cells may not possess the 
appropriate cross-reacting chemokines and/or adhesion molecules to enter the secondary 
lymphoid organs of mice. Thus, while there is significant homeostatic proliferation going
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on in my model, it is not clear that it contributes to the observed allograft response, which 
appears to depend solely on memory T cells.
My model provides the unique opportunity to study the role o f human memory T 
cells in allograft rejection. I chose to focus on the effects o f costimulation blockade, but 
certainly there are a number of studies that could be carried out in my model to study the 
regulation of memory T cells. In particular, the role o f regulatory T cells or peripheral 
tolerance in memory T cell mediated rejection would be interesting topics to pursue in 
future studies.
CD28 costimulation in memory T cell mediated rejection
Costimulation of T cells through CD28 by EC has been a contentious issue 
largely because of differences in results between experiments with human cells compared 
with other animals. In humans, HUVEC initially activate T cells independently of CD28 
(98, 188, 197) and in fact do not express any B7 molecules (188, 397). In contrast, 
mouse and porcine EC express CD80 and CD86 respectively (239, 388) and can utilize 
these molecules to activate naive T cells (219). Despite these differences, it is clear that 
agents targeting the CD28-B7 pathway have no effect on the initial stimulation that 
human EC provide to T cells. However, the question o f whether CD28 mediated 
signaling plays any role in the ensuing reaction remains unclear. Denton et al have 
shown that while HUVEC themselves do not express B7 molecules, HUVEC can 
stimulate CD4+ T cells to express CD86 and CD80 in culture (190). Thus, in Chapter 4 I 
used a novel reagent that blocks CD28 to try and identify the effects of this reagent on 
possible B7 interactions in co-cultures of T cells and EC. In characterizing this reagent, I 
discovered that the reagent, a monoclonal antibody, is actually partially costimulatory
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except in the presence of high levels o f B7 expression. However, the level of 
costimulation is less than the typical antibodies used for costimulation (Chapter 4). The 
partial costimulatory activity made it difficult to assess the effects of CD28 blockade in 
vitro other than the interesting point that in the presence of excess B7.2 that the antibody 
did not inhibit CD4+ T cell IFN-y production, while it did inhibit IL-2 production. This 
may be due to the fact that CD4+ IFN-y production may be much more sensitive to the 
level of B7 stimulation and the small amount of blockade that is not inhibited by the 
antibody may augment IFN-y production.
Initial studies done in mice with CTLA-4Ig, which binds B7 molecules with high 
affinity and blocks their interaction with CD28, demonstrated much promise for 
inhibiting T cell reactions (288). In combination with anti-CD 154 blockade this 
combination proved to be very effective in preventing allograft rejection (289). As 
discussed in Chapter 4, one of the problems with CTLA-4Ig is that it has become 
increasingly evident that signals delivered from CTLA-4 binding B7 molecules is 
important for the function of regulatory T cells (398). Therefore, this antibody with the 
ability to specifically target CD28 provides an opportunity to deliver inhibitory CTLA-4 
signals while simultaneously preventing activating CD28 signals. Unfortunately, the two 
reagents could not be compared in vivo because CTLA-4Ig augmented the adoptive 
transfer leading to dramatic increases in the level of circulating human cells in my model 
(data not shown). With regards to FK734, despite the partial agonist activity in vitro I 
found that blocking CD28 in vivo is able to ameliorate memory T cell mediated allograft 
rejection. However, the effect of blockade is modest at best and this is consistent with 
my understanding of the resistance of memory T cells to CD28-B7 blockade (291).
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There is ample evidence in mice suggesting that memory T cells are less reliant on 
CD28-B7 signals than naive T cells (58, 60). While these studies suggest that other 
pathways may compensate for the loss o f CD28-B7 costimulation making memory T 
cells resistant to CD28-B7 blockade, it is important to note that in the normal memory T 
cell response the CD28-B7 pathway retains an large role because blockade of these 
alternative pathways alone do not delay allograft rejection (306). My findings further 
support this idea and suggest a role for CD28 mediated signals in memory T cell 
activation.
Thus, while memory T cells may be resistant to CD28 blockade, it may be that 
blockade of this pathway is needed for the other pathways to become prominent. To test 
this idea, again, combinations of blockade would be useful to identify the precise 
hierarchy of signals mediating the allograft rejection seen in my model. Based on the 
murine data, the most useful combination should be CD28 and 0X 40 blockade (306), 
though my data suggests that blockade of all three costimulatory pathways in addition to 
B7 and/or LFA-3 blockade would likely have the greatest effect.
Memory specific costimulators in memory T cell- mediated rejection
In contrast to CD28, which is expressed constitutively on naive T cells, the 
memory specific costimulators, ICOS, 4 -IBB and 0X40, are expressed only upon T cell 
activation. This suggests that their function is likely related to the effector/memory phase 
of T cell activation rather than the initial phase of T cell activation. As discussed above, 
EC also have a unique ability to activate memory T cells in partly LFA-3 dependent 
manner. In Chapter 5, I examined whether the EC capacity to activate memory T cells
130
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
depended on their expression o f these memory T cell-specific costimulators and if 
targeting these interactions could ameliorate graft rejection.
EC have been shown to express functional ICOS-L which is important for EC 
reactivation o f effector/memory T cells (86). In that study, Khayyamian et al examined 
HUVEC and demonstrated that HUVEC express ICOSL and that blockade of EC ICOSL 
partially inhibits the EC capacity to activate CD4+ T cells. My data with HDMEC 
corroborates the evidence from this study showing that HDMEC express ICOSL 
constitutively, upregulate it with TNF and that blocking ICOSL inhibits CD4+ and CD8+ 
cytokine production and proliferation (Chapter 5). The reduction in T cell cytokine 
production and proliferation was approximately 50% suggesting that ICOSL plays a 
significant, but partial role in EC mediated T cell activation.
ICOS-ICOSL interactions have been shown to play a significant role in transplant 
rejection. Studies in mice using an anti-ICOS mAb, an ICOS-Ig fusion protein, or 
transfer into an ICOS deficient recipient show prolonged survival of a mismatched 
cardiac allograft, though to a lesser extent than administration of CTLA-4Ig or an anti- 
CD40L mAb (303). Treatment with both CTLA-4Ig or anti-CD40L mAb and ICOS-Ig 
resulted in the long-term survival o f a cardiac allograft (302, 399) suggesting there may 
be a synergistic effect between the ICOS-ICOSL pathway and the CD40-CD154 or 
CD28-B7 pathways. The timing of the administration of blockade of the ICOS-ICOSL 
pathway can also appears to influence transplant rejection. Harada et al demonstrated in 
a major mismatch cardiac allograft model that delayed ICOS blockade was more 
effective that early ICOS blockade in prolonging allograft survival because early 
blockade targeted only CD4+ T cells while delayed blockade inhibited both CD4+ and
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CD8+ T ell expansion (365). All these studies focused on rejection mediated by mostly 
naive T cells and recent work using memory T cells generated by homeostatically 
proliferated memory T cells or by donor Ag priming suprisingly showed no effect of 
blocking the ICOS-ICOSL pathway alone or in combination with CD28/CD154 blockade 
on skin allograft rejection (306). My studies using the hu-SCID chimera showed an 
increase in intragraft ICOSL mRNA during rejection and that blocking the ICOS-ICOSL 
pathway could inhibit T cell mediated endothelial injury and intragraft expression of IL- 
2, 4, and 10 mRNA (Chapter 5). This contradicts the mouse data with memory T cells, 
but is consistent with studies done in mice using naive T cell recipients. One explanation 
for this difference is access o f the memory T cells to the secondary lymphoid organs. 
While memory T cells apparently do not need secondary lymphoid organs to mediate 
rejection, those derived from homeostatic proliferation in the absence of the secondary 
lymphoid organs have been shown to be inferior to antigen experienced memory T cells 
(61). My model does not allow memory T cells access to functional secondary lymphoid 
organs and as such this may explain the greater effect o f ICOS blockade in my system 
where T cells may rely more on ICOSL provided in the graft for activation without 
access to the secondary lymphoid organs.
4-1BBL expression on EC has not been described previously. I demonstrate in 
this thesis that 4-1BBL can be induced at a low level on the surface of HDMEC both in 
response to TNF and co-culture with allogeneic T cells (Chapter 5). It has been shown to 
be induced by CD40 and IL-1 signaling on DC, but these stimuli have not been tested in 
EC (169). Blockade of this pathway inhibits CD8+ T cell, but not CD4+ T cell, IFN-y 
and IL-2 production (Chapter 5). However, blockade does decrease both CD4+ and
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CD8+ T cell proliferation in response to EC. These data are in agreement with data 
showing that 4 -IBB signaling affects both CD4+ and CD8+ T cells, but has a stronger 
effect on the activation of CD8+ T cells (160, 400). One consideration to the data 
regarding 4 -IBB signaling is that 4-1BBL is also known to induce reverse signaling. In 
human monocytes, stimulating 4-1BBL enhances their activation and survival (172, 173). 
The effects of 4-1BBL signaling in EC have not been examined and will be important to 
explore further.
With regard to transplantation, using 4-lBBIg (401), blocking mAbs, or genetic 
ablation (305) to eliminated 4-1BB signals demonstrated prolonged graft survival in 
murine cardiac allograft models showing decreased T cell infiltration and vascular 
damage. In skin allografts, however, deletion o f 4-1BBL had no effect unless it was 
combined with ablation o f CD28 (364) or CD 154 and CD45RB blockade (402). Thus, 
for naive T cells targeting 4 -IBB can prolong graft survival in both skin and cardiac 
allografts possibly affecting CD8+ T cell effector function. In one study looking at 
memory T cells derived from homeostatic proliferation or donor specific priming there 
was no effect of an anti-4-1BBL mAh (306). My data again contradicts the results in the 
murine model of memory and instead supports the data for naive T cells. In Chapter 5, 
administration of a blocking 4-1BBL mAb ameliorated memory T cell mediated allograft 
rejection and showed decreased intragraft IFN-y and IL-2 (Chapter 5). There was no 
change in T cell infiltration or perforin/granzyme B mRNA so it is not clear if decreased 
cytolytic function of CD8+ T cells is the mechanism of protection. The discrepancy 
between my model and the murine model may again lie in the lack of access to functional 
secondary lymphoid organs in my model compared to the murine model. Blockade of the
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4-1BB-4-1BBL pathway in EC-T cell co-cultures showed effects on CD4+ and CD8+ T 
cells and without access to other signals in the secondary lymphoid organs this pathway 
may be more important in my model than in the murine model.
The final pathway I examined in Chapter 5 was the OX40-OX40L pathway. 
OX40L expression on HUVEC has been described previously and been shown to mediate 
both adhesion to EC as well as costimulation with a polyclonal activator (152, 153). I 
demonstrate in Chapter 5 that HDMEC constitutively express significant levels of 
OX40L and that stimulation with TNF or co-culture with T cells increased those levels 
slightly. Blockade of OX40L in co-cultures led to decreased IFN-y and IL-2 production 
from both CD4+ and CD8+ T cells. This supports observations from other groups that 
have shown that in mice agonistic anti-OX40 antibodies enhance the expansion of both 
CD4+ and CD8+ T cells in vivo (403, 404).
In allograft responses, 0X 40 has emerged as a key player in the activation of 
memory T cells. Initial work in mice with OX40L showed that in alloresponses DC 
deficient in OX40L induced less effector cytokine production and weaker CTL 
generation (150, 405). Work from GVHD murine models have suggested that 0X 40 
deficiency has a much greater impact on CD4+ T cells compared to CD8+ T cells (406, 
407). The Sayegh group further demonstrated a critical role for OX40-OX40L signaling 
in both CD28/CD154 independent rejection and memory T cell mediated rejection in 
conjunction with CD28/CD154 blockade (306, 366). This data supports the observation 
that blockade of OX40L has significant impact on memory T cell mediated allograft 
rejection. OX40L blockade produced the greatest reduction in intragraft IFN-y, IL-2, IL- 
4, FasL and perforin mRNA expression in comparison to the other memory costimulators
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suggesting that blockade of OX40L in my model likely has strong effects on both CD4+ 
and CD8+ T cells.
In sum, I found that blockade of any o f these three memory T cell specific 
costimulators can reduce allograft injury significantly, but not completely. Interestingly, 
all three of these costimulatory molecules can be found on the surface of HDMEC and 
blockade o f any o f them can partially inhibit EC-mediated memory T cell activation for 
both CD4+ and CD8+ T cells. From my studies, it is not clear if  the effects that I have 
observed here are redundant and testing blockade in different combinations will be 
important to understand if they have overlapping function. It may also be useful to know 
if they have additive function with LFA-3, which is the original costimulatory molecule 
described on EC. More detailed data about the numbers and phenotype of CD4+ and 
CD8+ T cells infiltrating the graft might also shed some light as to whether these 
costimulatory molecules work by similar or distinct mechanisms.
Another interesting issue to pursue is one raised in the discussion of 4-1BBL, the 
idea that reverse signaling of the costimulatory molecule to their respective ligand may 
be occurring in EC. While it is not clear if  ICOSL has signaling function, there is 
evidence to suggest that ligation and signaling through B7-molecules may have important 
regulatory function in DC (408, 409) and B cells (410). Evidence for reverse signaling in 
the TNFR family is much stronger with evidence supporting bi-directional signaling for 
CD40/CD154 (411) and 4-1BB/4-1BBL (172, 173). Recent evidence using EC have 
shown that OX40L ligation can induce the production CXCR5 (412) and RANTES (413) 
suggesting that OX40L may also have signaling capabilities. As all my antibodies 
involve blockade of these ligands, it is possible that the effects that I have observed may
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be mediated by positive signaling in EC or other cells expressing the appropriate ligand 
in addition to blockade of the signal delivered to T cells. This issue requires further study 
to identify whether reverse signaling is occurring in EC and, if  it is, what are the 
functional consequences of such signaling on the EC capacity to activate memory T cells.
The response o f  memory T cell subsets to EC and their role in allograft rejection
As described in the Introduction and Chapter 6, human and mouse memory T cell 
can be broadly divided into two groups based on effector function and homing capacity 
(46, 51, 54). Tcm home to lymph nodes and have limited effector function, but have a 
large proliferative capacity and become effector cells upon restimulation. TEm on the 
other hand can home to peripheral tissues, rapidly produce IFN-y upon antigenic 
stimulation, but have limited proliferative potential. These distinctions were first 
described by Sallusto et al using polyclonal activators and little is known about the 
response of these different subsets to the endothelium. In considering how the two 
subsets would respond, there are two likely possibilities to consider. The first is given 
that Tem would typically see EC in the periphery I expected Tem to respond as they would 
to polyclonal stimulation and since Tcm likely depend upon DC mediated activation in 
the lymph nodes that, like naive T cells, they would not respond to allogeneic EC. The 
second possibility is that both subsets would respond similarly as they do to polyclonal 
activators with Tem favoring effector cytokines and Tcm favoring IL-2. It is the second 
hypothesis that proved to be true, that in response to EC T e m  produced more IFN-y and 
less IL-2, whereas TCm produced more IL-2 and less IFN-y. Their corresponding 
proliferative capacity is also consistent with the original observations that like the
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response to polyclonal activators in response to EC, T Cm  possess greater proliferative 
capacity than T Em - Co-culture of the different subsets with Mo showed a different pattern 
with T Cm  producing equivalent amounts of IFN-y as T Em  though T Em  still produce less 
IL-2. One explanation for this difference may be differences in the costimulatory 
capacity o f EC compared to Mo.
In examining the two subsets for a variety of costimulatory and adhesion 
molecules, I found that TEm express less CD27, CD28, CD152 (CTLA-4), 4-1BB, ICOS, 
LFA-1 and PD-1 when compared to Tcm- I decided to examine the role that CD27 and 
CD28 played in this difference in activation because of the corresponding difference in 
expression o f the ligand on EC versus Mo. For IFN-y, about 50% of Tcm and TEm 
production depended on signals from CD27 in co-cultures with EC, whereas co-cultures 
with Mo did not depend on CD27 signaling at all. For IL-2, about 50% of Tcm IL-2 
production depended on CD27 costimulation for both EC and Mo, but TEm IL-2 
production seems to be independent of CD27 signals. Studies from the Lipsky group 
showed that CCR7-CD27+ T cells produce more IFN-y compared to the CCR7+CD27+ 
or CCR7-CD27- and my TEM population does have a small percentage of CD27+ cells 
(Figure 6.3A) and this may explain why both Tcm and TEM IFN-y production may depend 
on CD27 signaling (131). The fact that IFN-y production was not affected in co-cultures 
with Mo could be because CD28 signals in Mo may mask any effect of CD27 signals on 
IFN-y production. IL-2 production is consistent with observations from the Lipsky group 
that Tcm, which express CD27 highly, produce a greater amount of IL-2 than Tem, and it 
appears that CD27 signaling may mediate part of the difference in IL-2 production 
between Tcm and TEm in response to EC or Mo.
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Due to the differences in B7 expression on the surface of EC compared Mo and 
the relative importance of B7 signaling for T cell activation, a likely explanation for the 
different responses of the T cell subsets may lie in the ability of the two different APC to 
deliver CD28 mediated signals. The slight reduction in CD28 expression on Tem also 
suggests that Tem may not be as sensitive to B7 mediated signals. The observations in 
Chapter 6 are consistent with work in Rhesus macaques where Pitcher et al found that 
T Cm  express CD28, whereas TEM do not (414) and experiments from Fontenot et al who 
studied beryllium specific T cells in humans and found a gradual decrease in CD28 
expression and dependence when memory T cells convert from T c m  to T Em  (415). Given 
my observations and the data from these other groups I was surprised to find that CTLA- 
4Ig blockade of B7-signaling affected both T c m  and T Em  cytokine production co-cultures 
with Mo, however consistent with data from other groups I found that the percent 
reduction in Tcm cytokine production was several fold higher than that o f Tem suggesting 
that T c m  have a greater reliance on CD28 signaling. It was also interesting to find that 
CTLA-4Ig also had significant effects on IL-2 production from both subsets in cultures 
with EC though again there was a much greater effect on T c m  compared to T Em - It is not 
clear where the B7 signals are coming from in co-cultures with EC and the reduction in 
IL-2 may be related to the trans-costimulation effect observed in co-cultures with EC 
from Denton et al (190). When the different subsets were co-cultured with EC 
expressing B7.2, the difference in IFN-y production was abolished while the difference in 
IL-2 production was retained. Thus, addition of B7.2 signals on the surface of EC 
enhanced the T c m  production of IFN-y suggesting that T Cm  are more sensitive to B7-
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signals. Therefore CD28 signaling may underlie the difference between EC and Mo 
activation of the Tcm subset.
In conclusion, I find that Tem produce more IFN-y versus Tcm in response to 
allogeneic EC but not with Mo. I believe that this difference in activation may be due to 
the ability of Mo to deliver B7 signals to the Tcm whereas EC cannot. It appears that Mo 
activate both subsets to produce IFN-y via CD28 without needing CD27 signals and the 
increased sensitivity of Tcm to CD28 signaling allows them to produce equivalent or 
more IFN-y compared to Tem in response to Mo. Since EC do not express B7 molecules, 
it appears that EC rely on CD27 to enhance Tem IFN-y production in combination with 
some other unknown signals. It seems that CD27 works in conjunction with other 
signals to augment cytokine production for IL-2 as well. From my data it appears that 
both EC and Mo stimulate T Cm  and T Em  to produce IL-2 at a certain level likely through 
CD28 and that additional IL-2 production by Tcm relies on CD27 signals.
Using my model of allograft rejection I next sought to identify which of the 
memory T cell subsets could mediate allograft rejection. Interestingly, only Tem and not 
Tcm could mediate allograft rejection in my model. This does not agree with Adams et al 
who studied heterologous memory in mice and showed that CD8+ Tcm were significantly 
more effective at mediating allogeneic skin graft rejection than CD8+ T Em  (275). One 
reason for the differences in my results is again that my model lacks functional secondary 
lymphoid organs as the adoptively transferred human T cells do not effectively circulate 
through the murine lymph nodes or spleen. While it has been shown that both CD4+ and 
CD8+ memory T cells of both subsets can survive and function without secondary 
lymphoid organs (416), one hypothesis is that once Tcm in my model are deprived of key
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signals like B7 that they would ordinarily receive in secondary lymphoid organs they 
cannot attain full effector function. Another related possibility is that the Tcm may be 
able to mediate rejection, but can not appropriately home to a peripheral organ without 
first encountering secondary lymphoid organs. Studies from my lab have shown that TEm 
can migrate in response to inflammatory chemokines presented on EC whereas Tcm 
cannot. This may indicate that even though Tcm can produce IL-2 and some IFN-y in 
response to EC, they might never get the chance to mediate rejection in my model 
because of their failure to transmigrate across the endothelium (417). Thus, in my model 
Tem, but not Tcm, can mediate allograft rejection and I speculate that this may be due to 
deficiencies in costimulation and/or homing.
Final Conclusions
In this thesis I have provided evidence that expands my current understanding of 
both the mechanisms and details of EC-mediated activation of memory T cells. I find 
that EC derived from human skin (HDMEC) can activate memory T cells and that EC use 
newly described memory T cell specific costimulators to do so. I also describe a model 
to study memory T cell mediated allograft rejection in vivo using human T cells. Using 
this model I find that memory T cell specific allograft rejection can be mediated in part 
by both B7 mediated costimulation and the memory T cell specific costimulators. I also 
characterize the response of difference memory T cell subsets to the endothelium and 
find that TCm respond differently than TEM to EC compared to Mo. I provide evidence to 
suggest that this difference may be due to differences in CD28 and CD27 signaling 
provided by EC versus Mo. Finally I show that in my model of peripheral rejection that 
Tem but not Tcm can mediate an allograft response.
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Recognizing that EC mediated activation of memory T cells plays a critical role in 
allograft rejection, I propose that EC use the newly described memory specific 
costimulatory molecules, ICOSL, 4-1BBL, and OX40L to activate memory T cells. 
These pathways in addition to the classic B7 pathway are important in memory T cell 
mediated rejection. The mechanism by which the costimulatory molecules interact with 
each other is unclear. In particular, the effects of reverse signaling on the endothelium or 
the signaling pathways they stimulate in T cells and EC remain poorly understood. These 
are concepts that will need to be explored further.
In addition to the unique costimulatory properties of EC, I also propose that the 
subset of memory T cells known as effector memory T cells through their capacity to 
express effector molecules in response to EC can directly mediate peripheral rejection 
whereas central memory T cells in response to EC do not fully differentiate and therefore 
lack the ability to mediate peripheral rejection. It is not clear whether it is lack of 
costimulation, difficulties in homing or some other mechanism like differences in T cell 
repertoire that prevents the Tcm from mediating rejection in vivo and these will be an 
important questions to address in future studies.
The identification of important costimulatory pathways and the introduction of a 
new model of allogeneic memory T cell responses may have important implications for 
studying and ameliorating allograft rejection.
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